

ENDO PHARMACEUTICALS HOLDINGS INC

Form DEF 14A

April 27, 2012

Table of Contents

UNITED STATES SECURITY AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF

THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO.)

x Filed by the Registrant .. Filed by a Party other than the Registrant
Check the appropriate box:

- .. Preliminary Proxy Statement
- .. **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)).**
- x Definitive Proxy Statement
- .. Definitive Additional Materials
- .. Soliciting Material Pursuant to Section 240.14a-12

ENDO PHARMACEUTICALS HOLDINGS INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (check the appropriate box):

- x No fee required
- .. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies

(2) Aggregate number of securities to which transaction applies

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined)

(4) Proposed maximum aggregate value of transaction

(5) Total fee paid

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid

(2) Form, Schedule or Registration Statement No.

(3) Filing Party

(4) Date Filed

Table of Contents

Endo
100 Endo Boulevard
Chadds Ford, PA 19317
610.558.9800
endo.com

April 27, 2012

Dear Fellow Endo Pharmaceuticals Holdings Inc. Stockholder:

It is my pleasure to invite you to the Annual Meeting of Stockholders of Endo Pharmaceuticals Holdings Inc. (the Company), which will be held on May 23, 2012 at 10:00 a.m., local time, at our corporate headquarters located at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317.

At the meeting, we will be electing nine members of our Board of Directors, voting to ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm, conducting an advisory vote on the compensation of our named executive officers and voting to approve the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to change the name of the Company to Endo Health Solutions Inc. In addition to these formal items of business, we will report on our Company's performance.

We look forward to seeing you at the Annual Meeting should you be able to attend. If you do plan to attend, please bring the enclosed Stockholder Admission Ticket with you.

Your vote is important. Whether you plan to attend the meeting or not, we encourage you to read this Proxy Statement and vote your shares. Please sign, date and return the enclosed proxy card as soon as possible in the postage-paid envelope provided. You may revoke your proxy at any time before it is exercised as explained in this Proxy Statement.

Thank you for your continued interest in Endo.

Very truly yours,

DAVID P. HOLVECK
President and Chief Executive Officer

April 27, 2012

This Proxy Statement and the accompanying proxy card are being mailed to stockholders on or about April 27, 2012.

endo | AMS Endo Pharmaceuticals HealthTronics Qualitest

Table of Contents

Endo
100 Endo Boulevard
Chadds Ford, PA 19317
610.558.9800
endo.com

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON MAY 23, 2012

Notice is hereby given that the 2012 Annual Meeting of Stockholders of Endo Pharmaceuticals Holdings Inc., a Delaware corporation, will be held on May 23, 2012 at 10:00 a.m., local time, at our corporate headquarters located at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317.

The purposes of the meeting are:

- (1) To elect nine directors, representing all of the members of the Board of Directors of the Company, to serve until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified;
 - (2) To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2012;
 - (3) To conduct an advisory vote on the compensation of our named executive officers;
 - (4) To amend and restate the Company's Amended and Restated Certificate of Incorporation to change the name of the Company to Endo Health Solutions Inc.; and
 - (5) To act upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.
- Only stockholders of record at the close of business on April 9, 2012 are entitled to notice of and to vote at the 2012 Annual Meeting and any adjournment thereof.

It is important that your shares be represented and voted at the Annual Meeting. Please vote by MARKING, SIGNING, DATING AND PROMPTLY RETURNING the enclosed proxy card as promptly as possible in the postage-paid envelope provided so that, whether you intend to be present at the Annual Meeting or not, your shares can be voted. Returning your proxy card will not limit your rights to attend or vote at the Annual Meeting.

By order of the Board of Directors,

CAROLINE B. MANOGUE
Executive Vice President, Chief Legal Officer & Secretary

Chadds Ford, Pennsylvania

April 27, 2012

endo | *AMS* *Endo Pharmaceuticals* *HealthTronics* *Qualitest*

Table of Contents

Proxy Statement for 2012 Annual Meeting of Stockholders

Table of Contents

<u>General Information</u>	1
<u>Annual Meeting Admission</u>	1
<u>Stockholders Entitled to Vote</u>	1
<u>How to Vote if You Are a Stockholder of Record</u>	1
<u>Electronic Access to Investor Information</u>	1
<u>General Information on Voting and Required Vote</u>	2
<u>Proposal 1: Election of Directors</u>	3
<u>Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm</u>	13
<u>Proposal 3: Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay Vote)</u>	14
<u>Proposal 4: Approval to Amend and Restate the Company's Amended and Restated Certificate of Incorporation to Change the Name of the Company to Endo Health Solutions Inc.</u>	16
<u>Compensation Discussion and Analysis</u>	17
<u>Compensation of Executive Officers and Directors</u>	34
<u>Other Information Regarding the Company</u>	43
<u>No Dissenters' Rights</u>	46
<u>Other Matters</u>	46
<u>Annual Report/Form 10-K</u>	46
<u>Stockholder Proposals for the 2013 Annual Meeting</u>	47

Table of Contents

Proxy Statement for 2012 Annual Meeting of Stockholders

General Information

We are providing these proxy materials in connection with the solicitation by the Board of Directors of Endo Pharmaceuticals Holdings Inc. (referred to as Endo, the Company, we, or us), a Delaware corporation, of proxies to be voted at our 2012 Annual Meeting of Stockholders to be held on May 23, 2012, beginning at 10:00 a.m., local time. The Annual Meeting will be held at our corporate headquarters located at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317.

This Proxy Statement and the enclosed proxy card are being mailed to stockholders on or about April 27, 2012.

Annual Meeting Admission

A Stockholder Admission Ticket is attached to your proxy card. If you plan to attend the Annual Meeting, please vote your proxy but keep the Stockholder Admission Ticket and bring it with you to the Annual Meeting.

If your shares are held beneficially in the name of a bank, broker or other holder of record and you plan to attend the Annual Meeting, you may present proof of your ownership of Endo stock, such as a bank or brokerage account statement, to be admitted to the Annual Meeting.

Stockholders also must present a form of personal identification in order to be admitted to the Annual Meeting. Directions to the site of the Annual Meeting are available on our website at <http://www.endo.com/Locations.aspx>.

No cameras, recording equipment or electronic devices will be permitted in the Annual Meeting.

Stockholders Entitled to Vote

Holders of shares of Endo common stock at the close of business on April 9, 2012 (the record date), are entitled to receive this notice and to vote their shares at the Annual Meeting. As of that date, there were 117,094,009 shares of Endo common stock outstanding and entitled to vote.

Each share of common stock is entitled to one vote on each matter properly brought before the Annual Meeting. Your proxy card indicates the number of votes you have.

How to Vote if You Are a Stockholder of Record

Your vote is important. Stockholders of record can vote by Internet, by mail or by attending the Annual Meeting and voting by ballot as described below.

Vote by Internet

If you choose to vote by Internet, simply visit www.proxyvote.com, enter the control number found on the enclosed proxy card and follow the steps outlined on the secure website.

Vote by Mail

If you choose to vote by mail, simply mark your proxy card, date and sign it, and return it in the postage-paid envelope provided.

Voting at the Annual Meeting

Voting by mail will not limit your right to vote at the Annual Meeting if you decide to attend in person. If your shares are held in the name of a bank, broker or other holder of record, you must obtain a proxy, executed in your favor, from the holder of record to be able to vote at the Annual Meeting.

All shares that have been properly voted and not revoked will be voted at the Annual Meeting. If you sign and return your proxy card but do not give voting instructions, the shares represented by that proxy will be voted FOR each of the nominees for election as director, FOR the ratification of the appointment of Deloitte & Touche LLP as the Company's registered public accounting firm for the year ending December 31, 2012, FOR the approval, on an advisory basis, of the compensation to be paid to Endo's named executive officers and FOR the approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to change the name of the Company to Endo Health Solutions Inc.

Electronic Access to Investor Information

Endo's Proxy Statement and other investor information are available on our Company's website at www.endo.com, under Investors. You can also access the Investor page of our website by scanning the QR code to the right with your smartphone.

Table of Contents

General Information on Voting and Required Vote

You are entitled to cast one vote for each share of Endo common stock you own on the record date. Provided that a quorum is present, (1) in order for a nominee to be elected as a director, such nominee must receive more votes for than against, (2) the approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation will require the affirmative vote of the holders of a majority of the issued and outstanding shares of the common stock and (3) the ratification of the appointment of the Company's registered public accounting firm and (4) the approval, on an advisory basis, of the compensation to be paid to Endo's named executive officers will each require the affirmative vote of a majority of shares entitled to vote and represented at the Annual Meeting in person or by proxy.

The presence of the holders of a majority of the outstanding shares of common stock as of the record date entitled to vote at the Annual Meeting, present in person or represented by proxy, is necessary to constitute a quorum. Shares represented by a proxy marked abstain on any matter will be considered present at the Annual Meeting for purposes of determining a quorum. Abstentions will have no effect on the election of the nominees, but will have the effect of a vote against the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation, the ratification of the appointment of the Company's independent registered public accounting firm and the approval, on an advisory basis, of the compensation to be paid to Endo's named executive officers. Shares represented by a proxy as to which there is a broker non-vote (for example, where a broker does not have the discretionary authority to vote the shares), will be considered present for the Annual Meeting for purposes of determining a quorum, and will have no effect on the vote with respect to the election of directors or the proposal to approve, on an advisory basis, the compensation to be paid to Endo's named executive officers. Broker non-votes, if any, will have the effect of a vote against the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation. Broker non-votes, if any, will have the effect of a vote against the ratification of the appointment of the Company's independent registered public accounting firm.

All shares of common stock that have been properly voted and not revoked, will be voted at the Annual Meeting in accordance with your instructions. If you sign, date and return the enclosed proxy card but do not give voting instructions, the shares of common stock represented by that proxy will be voted FOR each of the nominees for election as director, FOR the ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2012, FOR the approval, on an advisory basis, of the compensation to be paid to Endo's named executive officers and FOR the approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to change the name of the Company to Endo Health Solutions Inc.

Voting on Other Matters

If other matters are properly presented at the Annual Meeting for consideration, the persons named in the enclosed proxy card will have the discretion to vote on those matters for you. At the date the Company began printing this Proxy Statement, no other matters had been raised for consideration at the Annual Meeting.

How You May Revoke or Change Your Vote

You can revoke your proxy at any time before it is voted at the Annual Meeting by:

- sending written notice of revocation to the Secretary of the Company;
- timely delivering a valid, later-dated proxy; or
- attending the Annual Meeting and voting in person. If your shares are held in the name of a bank, broker or other holder of record, you must obtain a proxy, executed in your favor from the holder of record, to be able to vote at the meeting.

List of Stockholders

The names of stockholders of record entitled to vote at the Annual Meeting will be available at the Annual Meeting and for ten days prior to the Annual Meeting for any purpose germane to the meeting, between the hours of 8:45 a.m. and 4:30 p.m., at our principal executive offices at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317, by contacting the Secretary of the Company.

Cost of Proxy Solicitation

The Company will pay for preparing, printing and mailing this Proxy Statement and we will pay the cost of soliciting proxies. Proxies may be solicited on our behalf by directors, officers or employees in person or by telephone, electronic transmission and facsimile transmission. The Company will reimburse banks, brokers and other custodians, nominees and fiduciaries for their out-of-pocket costs of sending the proxy materials to our beneficial owners. We have also retained MacKenzie Partners, Inc. to assist in soliciting proxies. We will pay MacKenzie Partners, Inc. a base fee of approximately \$12,500 plus reasonable out-of-pocket expenses for these services.

Table of Contents

Proposal 1: Election of Directors

The Board of Directors

The Amended and Restated Certificate of Incorporation of the Company provides that the number of directors of the Company shall be not less than seven nor more than eleven, the exact number of which shall be fixed from time to the time by resolution of the Board of Directors or by a resolution adopted by holders of a majority of the Company's common stock. On March 3, 2011, the Board of Directors, or Board, fixed the number of directors at nine, effective March 3, 2011.

Under the terms of the Company's charter and by-laws, directors need not be stockholders of the Company or residents of the State of Delaware. However, pursuant to the Stock Ownership Guidelines approved by the Board of Directors on December 10, 2010, each non-employee Director should, but is not required to have ownership of the Company's common stock equal in value to at least five times his or her current annual cash retainer to be achieved within five (5) years of joining the Board, or in the case of non-employee Directors serving at the time the Ownership Guidelines were adopted, within five (5) years of the date of the adoption, or December 10, 2015, as further described in the section titled "Common Stock Ownership Guidelines". Directors are elected for a one-year term and generally hold office until their successors have been duly elected and qualified. Directors may receive compensation for their services as determined by the Board of Directors. See "COMPENSATION OF EXECUTIVE OFFICERS & DIRECTORS" 2011 Compensation of Directors. A vacancy on the Board, or a newly created directorship resulting from any increase in the authorized number of directors, may be filled by a majority of the directors then in office, even though less than a quorum remains. A director appointed to fill a vacancy remains a director until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.

Currently, the Board of Directors consists of nine members. Currently serving as directors are Roger H. Kimmel, John J. De-lucca, David P. Holveck, Nancy J. Hutson, Ph.D., Michael Hyatt, William P. Montague, David B. Nash, M.D., M.B.A., Joseph C. Scodari and William F. Spengler. All of the current members are nominated by the Board of Directors of the Company for the election as directors of the Company.

The Board annually determines the independence of directors based on a review by the directors and the Nominating & Governance Committee. No director is considered independent unless the Board of Directors has determined that he or she has no material relationship with the Company, either directly or as a partner, shareholder or officer of an organization that has a material relationship with the Company. Material relationships can include commercial, industrial, banking, consulting, legal, accounting, charitable and familial relationships, among others. To evaluate the materiality of any such relationship, the Board has adopted categorical independence standards consistent with the NASDAQ Exchange listing guidelines. These standards are available on the Company's website at www.endo.com, under "Investors-Corporate Governance-Nominating & Governance Committee".

Members of the Audit, Compensation, and Nominating & Governance Committees must meet applicable independence tests of the NASDAQ.

The Board of Directors has affirmatively determined that eight of its nine current members are independent directors under the NASDAQ rules and regulations. The eight independent directors under the NASDAQ rules and regulations are Messrs. Kimmel, Delucca, Hyatt, Montague, Scodari, Spengler, Dr. Nash and Dr. Hutson. If the nominees recommended by the Board of Directors are elected at the 2012 Annual Meeting, eight of the Company's nine directors will be independent directors under the NASDAQ rules and regulations.

On an annual basis and upon the nomination of any new director, the Nominating & Governance Committee and the Board review directors' responses to a questionnaire asking about their relationships with the Company (and those of their immediate family members) and other potential conflicts of interest, as well as material provided by management related to transactions, relationships, or arrangements between the Company and the directors or parties related to the directors. The Nominating & Governance Committee has determined that the eight non-employee directors currently serving are independent, and that the members of the Audit, Compensation, and Nominating & Governance Committees also meet the independence tests referenced above. Specifically, the Nominating & Governance Committee and the Board have determined that all non-employee directors have not had during the last three years (i) any of the relationships listed above or (ii) any other material relationship with the Company that would compromise his or her independence. The Nominating & Governance Committee recommended this determination to the Board of Directors and explained the basis for its decision, and this determination was adopted by the full Board.

As of the date of this Proxy Statement, there are no material proceedings to which any director or executive officer of the Company, or any associate thereof, is a party that are adverse to the Company or any of its subsidiaries.

Between January 1, 2011 and December 31, 2011, the Board of Directors as a whole met eight times and acted by written consent on eight occasions. All members of the Board of Directors who are standing for election attended more than 85% of the Board meetings held during their respective terms and 75% or more of the combined meetings of the Committees of the Board of Directors on which they served in 2011.

Table of Contents**Nominees**

There are nine nominees for election as directors of the Company to serve until the 2013 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified or until his/her earlier death, resignation or removal. All of the nominees are currently serving as directors of the Company and were elected to the Board at the last annual meeting.

The table to the right sets forth the age and position currently held with the Company of persons nominated by the Board of Directors for election as directors of the Company.

Name	Age (as of May 23, 2012)	Position Currently Held With the Company
Roger H. Kimmel	65	Chairman of the Board
John J. Delucca	69	Director
David P. Holveck	66	President, Chief Executive Officer, Director
Nancy J. Hutson, Ph.D.	62	Director
Michael Hyatt	66	Director
William P. Montague	65	Director
David B. Nash, M.D., M.B.A.	56	Director
Joseph C. Scodari	59	Director
William F. Spengler	57	Director

The proposed nominees for election as directors have confirmed that they are each willing to serve as directors of the Company. If, as a result of circumstances not now known or foreseen, a nominee shall be unavailable or unwilling to serve as a director, an alternate nominee may be designated by the present Board of Directors to fill the vacancy.

The Board believes that each of the Company's directors is highly qualified to serve as a member of the Board and each has contributed to the mix of skills, core competencies and qualifications of the Board. When evaluating candidates for election to the Board, the Nominating & Governance Committee seeks candidates with certain qualities that it believes are important, including experience, skills, expertise, personal and professional integrity, character, business judgment, time availability in light of other commitments, dedication, conflicts of *Set forth below are summaries of*

interest, those criteria and qualifications described in each director's biography below and such other relevant factors that the Nominating & Governance Committee considers appropriate in the context of the needs of the Board of Directors. Although not specified in the charter, the Committee also considers ethnicity and gender when selecting candidates so that additional diversity may be represented on the Board. Our directors are highly experienced and have diverse backgrounds and skills as well as extensive track records of success in what we believe are highly relevant positions. A number of our directors also have served as directors of Endo for many years and the Company benefits from their knowledge of our history, operations and corporate philosophy. The Board believes that each director's service as the Chairman, Vice Chairman, President and Chief Executive Officer, Executive Vice President & Chief Financial Officer or Senior Executive of significant companies has provided the directors with skills that are important to serving on our Board.

*the background,
business experience
and descriptions
of the principal
occupation of each
of the Company's
current nominees
for election as
directors:*

ROGER H. KIMMEL is currently Chairman of the Board of Endo and is chairman of Endo's Nominating & Governance Committee and a member of Endo's Audit Committee and Transactions Committee. Mr. Kimmel became Chairman of the Board upon the retirement of founder Carol A. Ammon on May 30, 2007. Mr. Kimmel had been a Director of Algos Pharmaceutical Corporation since July 1996 and became a Director of Endo following its merger with Algos in July 2000. Mr. Kimmel has been Vice Chairman of Rothschild Inc., an investment banking firm, since January 2001. Previously, Mr. Kimmel was a partner of the law firm Latham & Watkins for more than five years. Mr. Kimmel is also a director of PG&E Corporation and Schiff Nutrition International, Inc. Mr. Kimmel has been Chairman of the Board of Trustees of the University of Virginia Law School Foundation (not-for-profit) since January 2009. He has been a public speaker on corporate governance issues and private equity transactions. Mr. Kimmel brings knowledge of the Company's business, history and culture to the Board and the Chairman position. Through his experiences as Vice Chairman of an international investment banking firm and as a former corporate lawyer, Mr. Kimmel brings a unique skill set to the Board, including leadership capabilities, business strategy insight, risk management skills, mergers and acquisition, corporate finance, international business and legal expertise. Mr. Kimmel also has extensive corporate governance experience from his services on other company boards and his previous legal experience.

Table of Contents

JOHN J. DELUCCA has been a member of the Board of Directors since 2006 and is the Chairman of Endo's Audit Committee and is a member of Endo's Compensation Committee. Mr. Delucca was Executive Vice President and Chief Financial Officer of the REL Consultancy Group, a business consulting firm, until his retirement in 2004. Prior to that, he served as Chief Financial Officer and Executive Vice President, Finance & Administration, of Coty, Inc., a fragrance and beauty products company, from 1999 to 2002. From 1993 to 1999, he was Senior Vice President and Treasurer of RJR Nabisco, Inc. During his career, he also served in executive positions for Hasco Associates, Inc., The Lexington Group, the Trump Group, International Controls Corp., and Textron, Inc. Mr. Delucca is currently a Non-Executive Director and chairs the Audit Committee of The Elliot Company, an industrial manufacturer. Mr. Delucca also serves as a Non-Executive Director and chairs the Audit Committee and is a member of the Compensation Committee of Elster Group, a publicly traded company providing integrated metering and utilization solutions to the gas, electricity and water industries. Through his senior executive roles and financial experience at various organizations, Mr. Delucca has expertise in financial analysis, financial statements, evaluation of business strategies, and contributes to the Board valuable leadership and risk management skills. Mr. Delucca also has extensive corporate governance experience from his services, both current and historical, on other company boards.

DAVID P. HOLVECK is President, Chief Executive Officer and a Director of Endo. Prior to joining Endo in April 2008, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson, a diversified healthcare company, since 2004. Mr. Holveck joined Johnson & Johnson as a Company Group Chairman in 1999, following the acquisition of Centocor, Inc., a biotechnology company, by Johnson & Johnson. Mr. Holveck was Chief Executive Officer of Centocor, Inc. at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories. Mr. Holveck is a member of the Board of Trustees for The Fund for West Chester University, as well as the Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), the University City Science Center and the Kimmel Center. Mr. Holveck's knowledge of the Company, its operations and the evolving healthcare environment is valuable to the Board of Directors in evaluating and directing the Company's future. Through his service on the boards of directors of other organizations as well as his prior senior executive positions at global pharmaceutical and healthcare product companies, Mr. Holveck has developed extensive knowledge of operational leadership, risk oversight and management, as well as the pharmaceutical and device industries.

NANCY J. HUTSON, Ph.D. has been a member of the Board of Directors since 2009 and is a member of Endo's Compensation Committee, Nominating & Governance Committee and Transactions Committee. Dr. Hutson retired from Pfizer, Inc. in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer's pharmaceutical R&D site, known as Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfizer, she led 4,500 colleagues (primarily scientists) and managed a budget in excess of \$1 billion. She currently is a director of Cubist Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc., and serves on the board of Planned Parenthood of Connecticut. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT which is dedicated to supporting the equestrian sport of dressage. Having 25 years of experience with Pfizer's Research and Development organization, Dr. Hutson brings to the Board valuable pharmaceutical discovery research abilities, scientific expertise and an immense knowledge of the pharmaceutical industry. Her years of senior executive experience also bring a strong skill set to our Board regarding operational leadership and evaluation of business strategy.

MICHAEL HYATT is currently a Director of Endo and is Chairman of Endo's Transactions Committee and a member of Endo's Nominating & Governance Committee. Mr. Hyatt had been a director of Algos Pharmaceutical Corporation since November 1996 and became a director of Endo following its merger with Algos in July 2000. Mr. Hyatt is currently a senior advisor to Irving Place Capital, a leading institutional private equity firm focused on making equity investments in middle-market companies. Until 2008, Mr. Hyatt was a Senior Managing Director of Bear Stearns & Co., Inc. In April 2009, Mr. Hyatt was appointed a director of Schiff Nutrition International, Inc., a publicly traded manufacturer and marketer of nutritional supplements. Through Mr. Hyatt's experiences as a senior investment professional, manager and advisor, he has gained expertise in evaluating business strategies, conducting financial analysis and analyzing companies' future prospects. His career experience makes him a skilled advisor who provides critical insight into financial matters.

Table of Contents

WILLIAM P. MONTAGUE has been a member of the Board of Directors since 2009 and is a member of Endo's Audit Committee, Nominating & Governance Committee and Transactions Committee. Mr. Montague served as Chief Executive Officer of Mark IV Industries, Inc., a leading global diversified manufacturer of highly engineered systems and components for transportation infrastructure, vehicles and equipment, from November 2004 until his retirement on July 31, 2008 and as Director from March 1996. He joined Mark IV Industries in April 1972 as Treasurer/Controller, serving as Vice President of Finance from May 1974 to February 1986, then Executive Vice President and Chief Financial Officer from February 1986 to March 1996 and then as President from March 1996 to November 2004. Mr. Montague is also a director of Gibraltar Industries, Inc., a publicly traded manufacturer and distributor of products for the building and industrial markets, and in December of 2010, Mr. Montague became a director of International Imaging Materials, Inc., a privately held company that manufactures and sells a variety of thermal transfer ribbons and certain inks. Mr. Montague's senior leadership experience as Chief Executive Officer and Director of Mark IV Industries, Inc. brings to the Board operational and business strategy insights and acquisition experience. His financial experience also brings strong financial and tax expertise to our Board.

DAVID B. NASH, M.D., M.B.A. was appointed to the Board in March 2011 and is a member of Endo's Compensation Committee. He is the founding dean of the Jefferson School of Population Health, located on the campus of Thomas Jefferson University in Philadelphia, Pennsylvania, having taken that position in 2008. Previously, Dr. Nash was the Chairman of the Department of Health Policy of the Jefferson Medical College from 2003 to 2008. Dr. Nash is internationally recognized for his work in outcomes management, medical staff development and quality-of-care improvement; his publications have appeared in more than 100 articles in major journals. Dr. Nash serves on the Board of Directors and is a member of the Audit Committee of Humana Inc., one of the nation's largest publicly traded health and supplemental benefits companies. Dr. Nash also has served as a member of the Board of Trustees of Catholic Healthcare Partners in Cincinnati, Ohio. The Board believes that Dr. Nash brings a set of attributes that enhance the Company's ability to help people achieve lifelong well-being. Dr. Nash is a widely recognized innovator in an emerging medical discipline that unites population health, health policy, and individual health.

JOSEPH C. SCODARI has been a member of the Board of Directors since 2008 and is Chairman of Endo's Compensation Committee and is a member of Endo's Transactions Committee. Mr. Scodari was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, a diversified healthcare company, and a Member of Johnson & Johnson's Executive Committee from March 1, 2005 until March 1, 2008. He joined Johnson & Johnson in 1999 as President of Centocor, Inc., a biotechnology company, when Johnson & Johnson acquired Centocor. At the time of that acquisition, he had been the President and Chief Operating Officer of Centocor and a member of Centocor's Board of Directors since December 1997. In 2001, he was named Johnson & Johnson Company Group Chairman for the North American pharmaceutical business, and became a member of the Johnson & Johnson Pharmaceuticals Group Operating Committee. In 2003, Mr. Scodari was named Johnson & Johnson Company Group Chairman, Global Biopharmaceutical Business. Mr. Scodari serves as a Non-Executive Director, chairs the Corporate Governance Committee and is a member of the Compensation Committee of Covance Inc., a publicly traded drug development service company. Prior to joining Centocor, Mr. Scodari served in various senior leadership roles at Sterling Drug and later, Rhone-Poulenc Rorer. Mr. Scodari's years of experience in the pharmaceutical industry and his senior leadership roles as Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson and President of Centocor bring to the Board extensive knowledge of the pharmaceutical industry as well as organizational and operational management expertise. Mr. Scodari also contributes valuable business strategy insights. Mr. Scodari also has extensive corporate governance experience from his services on other company boards.

WILLIAM F. SPENGLER has been a member of the Board of Directors since 2008 and is a member of Endo's Audit Committee and Compensation Committee. From November 2010 until February 2012, Mr. Spengler was President of ChromaDex Corporation, a publicly traded company that is a leader in the development of phytochemical and botanical reference standards and that discovers, develops and markets novel, natural ingredients that fill unmet needs for healthy dietary supplements, foods, beverages, cosmetics and pharmaceuticals. From October 2011 until February 2012, Mr. Spengler was a member of the ChromaDex Corporation Board of Directors. From July 2008 until November 2010, Mr. Spengler served as Executive Vice President and Chief Financial Officer of Smith & Wesson Holding Corporation, a global leader in safety, security, protection and sport. Until March 2008, he was Executive Senior Vice President and Chief Financial Officer at MGI Pharmaceuticals Inc., an oncology- and acute care-focused biopharmaceutical company, where he had worked since 2005. Prior to joining MGI Pharma, Mr. Spengler was Executive Vice President and Chief Financial Officer at Guilford Pharmaceuticals Inc., a bioscience company, from July 2004 to October 2005. From 2002 to 2004, Mr. Spengler served as President, Chief Operating Officer and Director of Osteoimplant Technology, Inc., an orthopedic products company. Mr. Spengler was previously a Vice President of Finance at Black & Decker, and prior to that spent 14 years in various finance, planning and business development positions at Bristol Myers Squibb. Through his senior executive roles and financial experience at various organizations, Mr. Spengler contributes expertise in financial analysis, financial statements, evaluation of business strategies, and brings to the Board valuable leadership and risk management skills.

endo | 100 Endo Boulevard | Chadds Ford, Pennsylvania 19317

6

Table of Contents

Vote Required

Provided that a quorum is present, the nominees for director receiving a majority of the votes cast at the Annual Meeting in person or by proxy will be elected.

Stockholder Communications with Directors

The Board has established a process to receive communications from stockholders. Stockholders may contact any member or all members of the Board, any Board committee, or any chair of any such committee by mail. To communicate with the Board of Directors, any individual director or any group or committee of directors, correspondence should be addressed to the Board of Directors or any such individual director or group or committee of directors by either name or title. All such correspondence should be sent c/o Corporate Secretary at Endo, 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317.

All communications received as set forth in the preceding paragraph will be opened by the office of our Secretary for the sole purpose of determining whether the contents represent a message to our directors. Any contents that are not in the nature of advertising, promotions of a product or service, or patently offensive material will be forwarded promptly to the addressee. In the case of communications to the Board or any group or committee of directors, the Secretary's office will make sufficient copies of the contents to send to each director who is a member of the group or committee to which the envelope or e-mail is addressed.

The Company does not have a policy on director attendance at annual meetings. David P. Holveck, Roger H. Kimmel, Michael Hyatt, and William P. Montague attended the 2011 Annual Meeting.

Corporate Governance Board Leadership Structure and Risk Oversight

Board Leadership Structure

We have a board leadership structure under which Mr. Kimmel serves as Chairman of the Board. Following the annual meeting, we will have eight other directors, each of whom is independent with the exception of our President and Chief Executive Officer, Mr. Holveck. Our Board currently has four standing committees, each of which is comprised solely of independent directors with a committee chair. In addition, the Board appoints other committees as the Board considers necessary from time to time.

The Board believes that the Chairman and the role of the President and Chief Executive Officer should be separate and that the Chairman should not be an employee of the Company. Further, the Board believes this separation serves the Company's shareholders best for setting our strategic priorities and executing our business strategy. We believe that our Board consists of directors with significant leadership, organizational and strategic skills, as discussed above. All of our independent directors have served as the Chairman, Vice Chairman, Chief Executive Officer, Chief Financial Officer, or Senior Executive of other companies. Accordingly, we believe that our independent directors have demonstrated leadership in large enterprises, many with relevant industry experience, and are well-versed in board processes and corporate governance. We believe that having directors with such significant leadership skills benefits our Company and our shareholders.

In accordance with our by-laws and our corporate governance guidelines, the Chairman is responsible for chairing Board meetings and setting the agenda for these meetings. Each director also may suggest items for inclusion on the agenda and may, at any Board meeting, raise subjects that are not on the agenda for that meeting. As required by our corporate governance guidelines, our independent directors meet separately, without management present, at each meeting of the Board. In addition, our Board committees regularly meet without members of management present.

As part of its annual self-evaluation process, the Board evaluates its leadership structure to determine whether the Board continues to believe that it provides the optimal governance structure and required leadership talent for Endo. We believe that having a President and Chief Executive Officer for our company with oversight of company operations, coupled with an experienced independent board Chairman and experienced independent directors, who have appointed four committee chairs, is the appropriate leadership structure for Endo.

On a regular basis, the Company's officers who are responsible for monitoring and managing the Company's risks, including our President and Chief Executive Officer, our Chief Operating Officer, our Executive Vice President & Chief Financial Officer, our Executive Vice President, Chief Legal Officer & Secretary, our Vice President, Controller and Principal Accounting Officer and our Senior Director of Internal Audit, make reports to the Audit Committee. The Audit Committee, in turn, reports to the full Board. While the Audit Committee has primary

The Board of Directors recommends a vote FOR the election of these nominees for election as directors.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

responsibility for overseeing risk management, our entire Board is actively involved in overseeing risk management for the Company by engaging in periodic discussions with Company officers as the Board may deem appropriate. In addition, each of our Board committees considers the risks within its respective areas of responsibility.

Table of Contents

Risk Oversight

The Board of Directors believes that one of its most important responsibilities is to oversee how management manages the various risks the Company faces and has delegated primary responsibility for overseeing the Company's Enterprise Risk Management (or ERM) program to the Audit Committee. It is management's responsibility to manage risk and bring to the Audit Committee's and the Board of Directors' attention the most material risks to the Company. The Company's head of internal audit, who reports independently to the Audit Committee, facilitates the ERM program under the sponsorship of our Executive Leadership Committee (or ELC), which includes our President and Chief Executive Officer; Chief Operating Officer; Executive Vice President & Chief Financial Officer; Executive Vice President, Chief Legal Officer & Secretary; Executive Vice President, Research & Development & Chief Scientific Officer; Executive Vice President, Human Resources; Executive Vice President, Enterprise Quality and Supply Chain; Executive Vice President, Corporate Compliance & Business Practices; Company Group President, AMS; and Company Group President, HealthTronics. Enterprise risks are identified and prioritized by management, and each risk is assigned by the Board to a Board committee or the full Board for oversight based on the nature of the risk area and the committee's charter. The committee or full Board agendas include discussions of individual risk areas throughout the year. Additionally, the Audit Committee agendas include periodic updates on the ERM process throughout the year. The Board level risk discussions are led by an assigned executive sponsor, from the ELC, for each risk area.

The Audit Committee also regularly reviews treasury risks (insurance, credit and debt), financial and accounting, legal and compliance risks, information technology security risks and other risk management functions. In addition, the Compensation Committee considers risks related to succession planning and the attraction and retention of talent as well as risks relating to the design of compensation programs and arrangements. The Compensation Committee also reviews compensation and benefits plans affecting Endo employees in addition to those applicable to our executive officers. The full Board considers strategic risks and opportunities and regularly receives detailed reports from the committees regarding risk oversight in their respective areas of responsibility.

Code of Conduct

The Board of Directors has adopted a Code of Conduct that applies to the Company's directors, executives (including its President and Chief Executive Officer and Executive Vice President & Chief Financial Officer) and employees. The Code is posted on the Company's website at www.endo.com, under Investors-Corporate Governance-Code of Conduct.

Common Stock Ownership Guidelines

The Board of Directors has adopted stock ownership guidelines (the Ownership Guidelines) both for non-employee Directors and for executive officers and senior management of the Company (collectively, Executive Management). The Board of Directors approved the Ownership Guidelines on February 21, 2008, and amended these Ownership Guidelines on April 28, 2010 to increase the required ownership of the President and Chief Executive Officer. The Board of Directors amended the Ownership Guidelines on December 10, 2010 to further increase the required ownership levels for non-employee Directors and for Executive Management. The Board believes that non-employee directors and Executive Management should have a significant equity position in the Company and that the Ownership Guidelines serve to further the Board's interest in encouraging a longer-term focus in managing the Company. The Board also believes that the Ownership Guidelines align the interests of its directors and Executive Management with the interests of stockholders and further promote Endo's commitment to sound corporate governance. The Ownership Guidelines are posted on the Company's website at www.endo.com, under Investors-Corporate Governance-Compensation Committee.

Ownership Guidelines for Non-Employee Directors

The Ownership Guidelines advise that each non-employee Director should have an ownership equal in value to at least three times his or her then current annual cash retainer. Non-employee Directors are expected to achieve the Ownership Guidelines within five (5) years of joining the Board, or, in the case of non-employee Directors serving at the time the Ownership Guidelines were adopted, within five (5) years of the date of adoption of the Ownership Guidelines or February 20, 2013. On December 10, 2010, the Board of Directors approved revised Ownership Guidelines, increasing ownership equal in value to at least five times his or her current annual cash retainer to be achieved within five (5) years of joining the Board, or in the case of non-employee Directors serving at the time the Ownership Guidelines were adopted, within five (5) years of the date of the adoption of these revised Ownership Guidelines, or December 10, 2015. Non-employee Directors are also expected to continuously own sufficient shares to meet the Ownership Guidelines once attained.

Review and Approval of Transactions with Related Persons

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

The Board of Directors has adopted written policies and procedures for review, approval and monitoring of transactions involving the Company and related persons (directors and executive officers or their immediate family members, or stockholders owning five percent or greater of the Company's outstanding stock). The policy covers any related person transaction that meets the minimum threshold for disclosure in the Proxy Statement under the relevant rules of the U.S. Securities and Exchange Commission (the SEC) (generally, transactions involving amounts exceeding \$120,000 in which a related person has a direct or indirect material interest).

Table of Contents

A discussion of our current related person transactions appears in this Proxy Statement under TRANSACTIONS WITH RELATED PERSONS, PROMOTERS AND CERTAIN CONTROL PERSONS.

Committees of the Board of Directors

The Board of Directors has a standing Audit Committee, Compensation Committee and Nominating & Governance Committee as well as a Transactions Committee. The following table shows the directors who are currently members or Chairman of each of these committees.

Name	Nominating &			
	Audit Committee	Compensation Committee	Governance Committee	Transactions Committee
Roger H. Kimmel	Member	-	Chairman	Member
John J. Delucca	Chairman	Member	-	-
David P. Holveck	-	-	-	-
Nancy J. Hutson, Ph.D.	-	Member	Member	Member
Michael Hyatt	-	-	Member	Chairman
William P. Montague	Member	-	Member	Member
David B. Nash, M.D., M.B.A.	-	Member	-	-
Joseph C. Scodari	-	Chairman	-	Member
William F. Spengler	Member	Member	-	-

Audit Committee

The Audit Committee is responsible for overseeing the Company's financial reporting process on behalf of the Board of Directors. In addition, the Audit Committee reviews, acts on and reports to the Board of Directors with respect to various auditing and accounting matters, including the selection of the Company's independent registered public accounting firm, the scope of the annual audits, fees to be paid to the independent registered public accounting firm, the performance of the Company's independent registered public accounting firm and the accounting practices of the Company and the Company's internal controls and legal compliance functions. The Audit Committee operates pursuant to a written charter adopted by the Board of Directors, which is available on the Company's website at www.endo.com, under Investors-Corporate Governance-Audit Committee. The charter describes the nature and scope of responsibilities of the Audit Committee.

Management of the Company has the primary responsibility for the Company's financial reporting process, principles and internal controls as well as preparation of its financial statements. The Company's independent registered public accounting firm is responsible for performing an independent audit of the Company's financial statements and expressing an opinion as to the conformity of such financial statements with accounting principles generally accepted in the United States.

Messrs. Kimmel, Delucca, Montague and Spengler currently serve as members of the Audit Committee and subject to their election at the 2012 Annual Meeting, the Board of Directors currently expects to reappoint Messrs. Kimmel, Delucca, Montague and Spengler as members of the Audit Committee, effective May 23, 2012. Between January 1, 2011 and December 31, 2011, the Audit Committee met 11 times, including periodic meetings held separately with management, the Company's internal auditors and the independent registered public accounting firm. Subject to his election at the 2012 Annual Meeting, the Board currently expects to reappoint Mr. Delucca as Chair of the Audit Committee. The Board has determined that Mr. Delucca is a financial expert, as defined by the SEC regulations, and he has the related financial management expertise within the meaning of the NASDAQ rules. The Board of Directors has determined that Messrs. Kimmel, Delucca, Montague and Spengler are independent and financially literate in accordance with the criteria established by the SEC and the NASDAQ.

Compensation Committee

The Compensation Committee of the Board of Directors determines the salaries and incentive compensation of the executive officers of the Company and provides broad guidance regarding the salaries and incentive compensation of the other employees of the Company. The Compensation Committee also reviews and acts on any recommendations of the Company's management for awards granted under the Endo Pharmaceuticals Holdings Inc. 2010 Stock Incentive Plan. The current members of the Compensation Committee are Messrs. Delucca, Nash, Scodari and Spengler and Dr. Hutson. Subject to their election at the 2012 Annual Meeting, the Board of Directors currently expects to reappoint Messrs. Delucca, Nash, Scodari and Spengler and Dr. Hutson as members of the Compensation Committee and to re-appoint Mr. Scodari as Chair of the Compensation Committee, effective May 23, 2012. Each of Messrs. Delucca, Nash, Scodari and Spengler and Dr. Hutson is

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

independent in accordance with the criteria established by the SEC and the NASDAQ. Between January 1, 2011 and December 31, 2011, the Compensation Committee met 8 times. The Compensation Committee operates pursuant to a written charter adopted by the Board of Directors, which is available on the Company's website at www.endo.com, under Investors-Corporate Governance-Compensation Committee. The charter describes the nature and scope of responsibilities of the Compensation Committee.

Table of Contents

The primary purpose of the Compensation Committee is to conduct reviews of the Company's general executive compensation policies and strategies and oversee and evaluate the Company's overall compensation structure and programs. The Compensation Committee confirms that total compensation paid to the President and Chief Executive Officer, Executive Vice President & Chief Financial Officer and those other individuals included in the Summary Compensation Table is reasonable and competitive. All of these individuals are referred to as the NEOs. Responsibilities of the Compensation Committee include, but are not limited to:

- evaluating and approving goals and objectives relevant to compensation of the President and Chief Executive Officer and other NEOs, and evaluating the performance of the executives in light of those goals and objectives;
- determining and recommending for approval by the Board of Directors the compensation level of the President and Chief Executive Officer;
- evaluating and approving compensation levels of the NEOs (and certain other employees);
- evaluating and approving all grants of equity-based compensation to the NEOs (and certain other employees);
- recommending to the Board compensation policies for outside directors;
- providing general compensation oversight on significant issues affecting the Company's compensation philosophy and/or policies;
- providing input to management on whether compensation arrangements for the NEOs (and certain other employees) incentivize excessive risk taking;
- reviewing performance-based and equity-based incentive plans for the President and Chief Executive Officer, other NEOs, and reviewing other benefit programs presented to the Compensation Committee by management;
- reviewing and approving the aggregate amount of dollars, in the case of the annual cash incentive compensation, and stock options, performance share units and restricted stock units, in the case of the annual long-term incentive compensation, that is available to the Company each year;
- reviewing at least annually the Company's succession plan relating to NEO positions and make recommendations to the Board related to the selection of individuals to hold the position of President and Chief Executive Officer; and
- reviewing and recommending to the Board for approval the annual goals and objectives of the Company as a whole, which in turn serve as the foundation for incentive compensation.

In August 2008, the Compensation Committee retained, and has continued to utilize throughout 2011, a compensation consultant from Hay Group for matters related to executive and director compensation. Hay Group is an outside global human resources consulting firm and does not provide any other services to the Company. Hay Group is asked to provide independent, third-party advice and expertise in executive compensation issues. The compensation consultant reports directly to the Committee. Hay Group provides the Compensation Committee with comparative market data and alternatives to consider when making compensation decisions and reviews the recommendations being made by the Company's management for executives. The Compensation Committee may retain other consultants and advisors from time to time.

Endo management is required to provide reviews and recommendations for the Compensation Committee's consideration, and to manage the Company's executive compensation programs, policies and governance. Direct responsibilities in this regard include, but are not limited to:

- providing an ongoing review of the effectiveness of the compensation programs for all employees, including competitiveness, and alignment with the Company's objectives;
- recommending changes, if necessary, to achieve all program objectives; and
- recommending pay levels, payout and/or awards for NEOs and certain other employees other than the President and Chief Executive Officer.

The Compensation Committee can exercise its discretion in modifying any recommended adjustments or awards to the NEOs.

Compensation Committee Interlocks and Insider Participation

None of the members of the Compensation Committee during 2011 or as of the date of this Proxy Statement is or has been an officer or employee of the Company and no executive officer of the Company served on the compensation committee or board of any company that employed any member of the Company's Compensation Committee or Board of Directors.

Nominating & Governance Committee

On December 13, 2006, the Board of Directors chartered the Nominating & Governance Committee, which is comprised of independent directors.

The Nominating & Governance Committee of the Board of Directors identifies and recommends to the Board individuals qualified to serve as directors of the Company, recommends to the Board directors to serve on committees of the Board and advises the Board with respect to matters of Board composition and procedures. The Nominating & Governance Committee also oversees the Company's corporate governance.

The Nominating & Governance Committee will consider director candidates recommended by stockholders. In considering candidates submitted by stockholders, the Nominating & Governance Committee will take into consideration the needs of

Table of Contents

the Board and the qualifications of the candidate. The Nominating & Governance Committee may also take into consideration the number of shares held by the recommending stockholder and the length of time that such shares have been held. To have a candidate considered by the Nominating & Governance Committee, a stockholder must submit the recommendation in writing and must include the following information:

The name of the stockholder and evidence of the person's ownership of Company stock, including the number of shares owned and the length of time of ownership; and

The name of the candidate, the candidate's resume or a listing of his or her qualifications to be a director of the Company and the person's consent to be named as a director if selected by the Nominating & Governance Committee and nominated by the Board.

The stockholder recommendation and information described above must be sent to the Secretary at Endo, 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317, and must be received by the Secretary not less than 120 days prior to the anniversary date of the Company's most recent annual meeting of stockholders.

While the Board does not have a formal policy with respect to diversity, the Board of Directors and the Nominating & Governance Committee advocate diversity in the broadest sense. We believe that it is important that nominees for the Board represent diverse viewpoints and have diverse backgrounds. The Nominating & Governance Committee looks at a broad array of qualifications and attributes including: experience, skills, expertise, and personal and professional integrity, character, business judgment, time availability in light of other commitments, dedication, conflicts of interest and such other relevant factors that the Nominating & Governance Committee considers appropriate in the context of the needs of the Board of Directors. Although not specified in the charter, the Committee actively considers ethnicity and gender when selecting candidates so that additional diversity may be represented on the Board.

The Nominating & Governance Committee identifies potential nominees by asking current directors and executive officers to notify the Nominating & Governance Committee if they become aware of persons meeting the criteria described above. The Nominating & Governance Committee also, from time to time, may engage firms that specialize in identifying director candidates. As described above, the Nominating & Governance Committee will also consider candidates recommended by stockholders.

Once a person has been identified by the Nominating & Governance Committee as a potential candidate, the Nominating Committee may collect and review publicly available information regarding the person to assess whether the person should be considered further. If the Nominating & Governance Committee determines that the candidate warrants further consideration, the Chairman or a member of the Nominating & Governance Committee contacts the person. Generally, if the person expresses a willingness to be considered and to serve on the Board, the Nominating & Governance Committee requests information from the candidate, reviews the person's accomplishments and qualifications, including in light of any other candidates that the Nominating & Governance Committee might be considering, and conducts one or more interviews with the candidate. Generally, Nominating & Governance Committee members may conduct additional due diligence of the candidate. The Nominating & Governance Committee's evaluation process does not vary based on whether or not a candidate is recommended by a stockholder, although, as stated above, the Board may take into consideration the number of shares held by the recommending stockholder and the length of time that such shares have been held.

The current members of the Nominating & Governance Committee are Messrs. Kimmel, Hyatt and Montague and Dr. Hutson. The Board has elected Mr. Kimmel as Chairman of the Nominating & Governance Committee. Between January 1, 2011 and December 31, 2011, the Nominating & Governance Committee met 6 times. Subject to their election at the 2012 Annual Meeting, the Board of Directors currently expects to reappoint Messrs. Kimmel, Hyatt and Montague and Dr. Hutson as members of the Nominating & Governance Committee and to re-appoint Mr. Kimmel as Chair of the Nominating & Governance Committee, effective May 23, 2012. The Board of Directors has determined that all of the members of the Nominating & Governance Committee are independent in accordance with the criteria established by the SEC and the NASDAQ. The Nominating & Governance Committee operates pursuant to a written charter adopted by the Board of Directors, which is available on the Company's website at www.endo.com, under Investors-Corporate Governance-Nominating & Governance Committee.

Transactions Committee

On July 31, 2007, the Board of Directors formed a Transactions Committee to provide advice and guidance to the Company's management in connection with the exploration of strategic acquisition and licensing opportunities as well as any overture for merger with the Company, or sale of the Company or other like event. The current members of the Transactions Committee are Messrs. Kimmel, Hyatt, Montague and Scodari and Dr. Hutson. Subject to their election at the 2012 Annual Meeting, the Board of Directors currently expects to reappoint Messrs. Kimmel, Hyatt, Montague and Scodari and Dr. Hutson as members of the Transactions Committee, and to reappoint Mr. Hyatt as the Chair of the Transactions Committee, effective May 23, 2012. Between January 1, 2011 and December 31, 2011, the Transactions Committee met 2 times.

Table of Contents

Audit Committee Report

The Audit Committee has reviewed and discussed the Company's audited consolidated financial statements as of and for the year ended December 31, 2011 with the management of the Company and Deloitte & Touche LLP, the Company's independent registered public accounting firm. Further, the Audit Committee has discussed with Deloitte & Touche LLP the matters required to be discussed under auditing standards generally accepted in the United States, including those matters set forth in the Statement of Auditing Standards No. 61, Communications with Audit Committees, as amended and as adopted by the Public Company Accounting Oversight Board in Rule 3200T, other standards of the Public Company Accounting Oversight Board (United States), rules of the SEC, and other applicable regulations, relating to the firm's judgment about the quality, not just the acceptability, of the Company's accounting principles, the reasonableness of significant judgments and estimates, and the clarity of disclosures in the consolidated financial statements.

The Audit Committee also has received the written disclosures and the letter from Deloitte & Touche LLP required by PCAOB Ethics and Independence Rule 3526, Communication with Audit Committees Concerning Independence, which relate to Deloitte & Touche LLP's independence from the Company, and has discussed with Deloitte & Touche LLP their independence from the Company. The Audit Committee has also considered whether the independent registered public accounting firm's provision of non-audit services to the Company is compatible with maintaining the firm's independence. The Audit Committee has concluded that the independent registered public accounting firm is independent from the Company and its management. The Audit Committee has also discussed with management of the Company and Deloitte & Touche LLP such other matters and received such assurances from them as it has deemed appropriate.

The Committee also reviewed management's report on its assessment of the effectiveness of the Company's internal control over financial reporting and the independent registered public accounting firm's report on the effectiveness of the Company's internal control over financial reporting. In addition, the Audit Committee reviewed key initiatives and programs aimed at strengthening the effectiveness of the Company's internal and disclosure control structure. As part of this process, the Audit Committee continued to monitor the scope and adequacy of the Company's internal auditing program.

Based on the reviews, reports and discussions referred to above, the Audit Committee recommended to the Board of Directors, and the Board approved, that the Company's audited consolidated financial statements for the year ended December 31, 2011 and management's assessment of the effectiveness of the Company's internal control over financial reporting be included in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, for filing with the SEC. The Audit Committee has selected, and the Board of Directors has approved, subject to stockholder ratification, the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2012.

Submitted by the Audit Committee of the Company's Board of Directors.

Members of the Audit Committee:

John J. Delucca (Chairman)

Roger H. Kimmel

William P. Montague

William F. Spengler

The above Audit Committee Report does not constitute soliciting material, and shall not be deemed filed or incorporated by reference into any other Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates the Audit Committee Report by reference therein.

Table of Contents**Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm**

The Audit Committee of the Board of Directors has selected Deloitte & Touche LLP, an independent registered accounting firm, to audit the books and financial records of the Company for the year ending December 31, 2012. The Company is asking its stockholders to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2012.

A representative of Deloitte & Touche LLP is expected to be present at the Annual Meeting and available to respond to appropriate questions, and will have the opportunity to make a statement if he or she desires to do so.

Vote Required

The affirmative vote of a majority of the issued and outstanding shares entitled to vote and represented at the Annual Meeting in person or by proxy will be required to approve the ratification of the appointment of the Company's registered public accounting firm. Abstentions will be counted and will have the same effect as a vote against the proposal.

The Audit Committee and the Board of Directors recommend a vote FOR the ratification of the Board's appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2012.

Fees Paid to the Independent Registered Public**Accounting Firm**

Deloitte & Touche LLP, the member firms of Deloitte Touche Tohmatsu, and their respective affiliates (collectively, the Deloitte Entities) served as the Company's independent registered public accounting firm for the year ended December 31, 2011. The table to the right summarizes the aggregate fees for services the Deloitte Entities provided during years 2011 and 2010.

	2011		2010	
Audit Fees ^a	\$	4,106,270	\$	1,984,038
Audit-Related Fees ^b	\$	541,425	\$	906,765
Tax-Fees ^c	\$	774,286	\$	631,855
All Other Fees	\$	-	\$	-
Total	\$	5,421,981	\$	3,522,658

- a Fees for audit services billed in 2011 and 2010 consisted of:
 Audit of the Company's annual financial statements;
 Evaluation and reporting on the effectiveness of the Company's internal controls over financial reporting;

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

Reviews of the Company's quarterly financial statements; and
Comfort letters, consents and other services related to debt issuances and other SEC matters.

Audit services grew year on year due to the expansion in both the size and scope of Endo Pharmaceutical Holdings Inc., in particular subsequent to the AMS and Qualitest acquisitions.

- b Fees for audit-related services billed in 2011 and 2010 consisted of:
 - Audit-related fees associated with acquisitions; and
 - Employee benefit plan audits.
- c Fees for tax services billed in 2011 and 2010 consisted of tax compliance and tax planning and advice.
 - Tax compliance services are services rendered based upon facts already in existence or transactions that have already occurred to document, compute, and assist the Company in obtaining government approval for amounts to be included in tax filings and consisted of:
 - i Federal, state and local income tax return assistance;
 - ii Sales and use, property and other tax return assistance; and
 - iii Assistance with tax return filings in certain foreign jurisdictions.

In considering the nature of the services provided by the Deloitte Entities, the Audit Committee determined that such services are compatible with the provision of independent audit services. The Audit Committee discussed these services with the Deloitte Entities and Company management to determine that they are permitted under the rules and regulations concerning auditor independence promulgated by the SEC to implement the Sarbanes-Oxley Act of 2002, as well as the American Institute of Certified Public Accountants.

Pre-Approval Policy

Consistent with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy to pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm.

Table of Contents

Prior to the engagement of the independent registered public accounting firm for the next year's audit, management will submit a list of services and related fees expected to be rendered during that year within each of the four categories of services to the Audit Committee for approval.

- 1 *Audit services* include audit work performed on the financial statements and related to the evaluation and reporting on the effectiveness of the Company's internal control over financial reporting, as well as work that generally only the independent registered public accounting firm can reasonably be expected to provide, including comfort letters, consents and other services related to SEC matters, and discussion surrounding the proper application of financial accounting and/or reporting standards.
- 2 *Audit-related services* are for assurance and related services that are traditionally performed by the independent registered public accounting firm, including due diligence related to mergers and acquisitions and employee benefit plan audits.
- 3 *Tax services* include all services, except those services specifically related to the audit of the financial statements, performed by the independent registered public accounting firm's tax personnel, including tax analysis; assisting with the coordination of execution of tax related activities, primarily in the area of corporate developments; supporting other tax related regulatory requirements; and tax compliance and reporting.
- 4 *Other Fees* are those associated with services not captured in the other categories.

Prior to engagement, the Audit Committee pre-approves the independent registered public accounting firm's services within each category. The fees are budgeted and the Audit Committee requires the independent registered public accounting firm and management to report actual fees versus budget periodically throughout the year by category of service. During the year, circumstances may arise when it may become necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval categories. In those instances, the Audit Committee requires specific pre-approval before engaging the independent registered public accounting firm.

The Audit Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting.

Proposal 3: Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay Vote)

Section 951 of the Dodd-Frank Wall Street Reform and Consumer Protection Act requires that we seek a non-binding advisory vote from our stockholders to approve the compensation of our named executive officers (NEOs) as disclosed in the COMPENSATION DISCUSSION AND ANALYSIS (CD&A) and tabular disclosures of this Proxy Statement. Since the required vote is advisory, the result of the vote is not binding upon the Board.

Endo's compensation philosophy is to pay for performance, support Endo's business strategies and offer competitive compensation arrangements. In the CD&A, we have provided stockholders with a description of the Company's compensation programs, including the philosophy and strategy underpinning the programs, the individual elements of the compensation programs and how our compensation plans are administered. Our compensation philosophy is designed to attract and retain highly-talented individuals and motivate them to achieve competitive corporate performance, while embracing the Company's values and leadership attributes. Our programs seek to:

- Create long-term shareholder value;
- Closely link compensation with company performance and individual performance;
- Appropriately reward achieving and exceeding the Company's strategic and business plans;
- Provide appropriate compensation for achieving annual results while also fostering a long-term performance orientation;
- Reflect the competitive market for talent; and
- Mitigate risk.

The Company's compensation programs consist of elements designed to complement each other and reward achievement of short-term and long-term objectives tied to the Company's performance through the establishment and achievement of strategic operating metrics or as a function of the Company's total shareholder return (stock price). We have chosen the selected metrics to align employee compensation, including compensation for the NEOs as disclosed in the Summary Compensation Table of this Proxy Statement, to the Company's strategic operating results and business strategy.

Table of Contents

The Compensation Committee regularly reviews industry practices related to executive compensation to better align the Company's compensation philosophy with the Company's business strategy, while reflecting an understanding of the external environment. Recent examples of Compensation Committee actions taken in an effort to best achieve pay for performance in NEO compensation are:

Revised our Data Point Companies (as defined below under the section entitled COMPENSATION DISCUSSION AND ANALYSIS) in order to appropriately compare each NEO's total compensation to executives in similar positions and with similar responsibilities at similar companies of comparable size.

For the annual cash Incentive Compensation (IC) program:

- i Expanded annual performance management process setting clear financial, strategic, portfolio and organizational goals utilizing well-defined scorecards across the Company's various business segments that closely links pay and performance;
- i Approved the Company's annual scorecard of objectives and metrics to reflect business conditions and the Company's strategy;
- i Increased the level of performance required to reach minimum, target, and maximum payout levels; and
- i Introduced profitability-based program funding criteria in addition to the financial metrics already included in the Company and business-level annual scorecards.

For the equity-based long-term incentives (LTI) program:

- i Revised the peer group used to measure relative total stockholder return performance for our performance share unit (PSU) awards, since the Standard and Poor's (S&P) 1500 Healthcare Index is more broadly representative of the overall healthcare environment in which the Company operates; and
- i Increased the level of performance required to achieve minimum, target and maximum payout levels associated with the Company's PSU cumulative target net sales objectives.

Conducted an assessment of the potential risks associated with compensation arrangements, policies and practices, confirming that the potential risks associated with our compensation policies and practices are not reasonably likely to have a material adverse effect on Endo.

In addition to the actions noted above, the Company has affirmatively determined not to offer new employees gross-up payments related to excise tax liabilities resulting from a change in control of the Company, as demonstrated by the employment agreements entered into with Mr. Holveck, Mr. Levin, Ms. McHugh and Dr. Gergel, which do not include an excise tax gross-up. Mr. Holveck and Dr. Gergel's employment agreements were amended further to exclude automatic renewal provisions.

As illustrated by these actions, the Compensation Committee has and will continue to take action to structure our executive compensation practices in a manner that is performance-based with a view towards maximizing long-term stockholder value. The Board believes that the executive compensation as disclosed in the CD&A, tabular disclosures, and other narrative executive compensation disclosures in this Proxy Statement aligns with our Data Point Companies' pay practices and coincides with our compensation philosophy.

Effect of Proposal

The above say-on-pay resolution is non-binding. The approval or disapproval of this proposal by stockholders will not require the Board or the Compensation Committee to take any action regarding the Company's executive compensation practices.

The Board values the opinions of the Company's stockholders as expressed through their votes and other communications. Although the resolution is non-binding, the Board will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

The Board recommends that you vote FOR the approval, on an advisory basis, of the compensation to be paid to Endo's named executive officers as described in the CD&A, tabular disclosures, and other narrative executive compensation disclosures in this Proxy Statement as required by the Securities and Exchange Commission.

Table of Contents

Proposal 4: Approval to Amend and Restate the Company's Amended and Restated Certificate of Incorporation to Change the Name of the Company to Endo Health Solutions Inc.

Description of the Amendment and Vote Required

The Board of Directors is requesting approval of an amendment and restatement to the Company's Amended and Restated Certificate of Incorporation to change the name of the Company to Endo Health Solutions Inc. (referred to as the Proposed Amendment) and has directed that the Proposed Amendment be submitted to the stockholders for approval at the Annual Meeting. If approved by the holders of a majority of the issued and outstanding shares of common stock, the Proposed Amendment will become effective upon the subsequent filing of the Proposed Amendment with the Delaware Secretary of State.

The Board recommends that you vote FOR the approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to change the name of the Company to Endo Health Solutions Inc.

Reasons For and Effects of the Proposed Amendment

On February 22, 2012, the Board of Directors of the Company adopted a resolution to change the name of the Company from Endo Pharmaceuticals Holdings Inc. to Endo Health Solutions Inc., and subject to the approval of the stockholders of the Company, to amend and restate the Company's Amended and Restated Certificate of Incorporation to effect such change in corporate name. The resolution also provided that the Proposed Amendment be presented to the stockholders for approval at the Annual Meeting with the recommendation of the Board of Directors that the stockholders approve the Proposed Amendment, all in accordance with Sections 242 and 245 of the Delaware General Corporation Law.

The Proposed Amendment is consistent with the Company's recent enterprise-wide branding initiative. The introduction of a new corporate identity, in conjunction with the aggregation of its four diversified operating units, reflects the Company's significant transformation as a result of a series of recent strategic acquisitions and business development decisions.

If the Proposed Amendment is approved and becomes effective, Article FIRST of the Company's Amended and Restated Certificate of Incorporation, which sets forth the Company's name, will be amended to read as follows: The name of the Corporation is Endo Health Solutions Inc.

Compensation Committee Report

The Compensation Committee reviewed and discussed with the Company's management the section of this Proxy Statement entitled "COMPENSATION DISCUSSION AND ANALYSIS". In reliance on this review and discussion, the Compensation Committee recommended to the Board of Directors that the section entitled "COMPENSATION DISCUSSION AND ANALYSIS" be included in this Proxy Statement and incorporated by reference into the Company's Annual Report on Form 10-K for the year ended December 31, 2011.

Submitted by the Compensation Committee of the Company's Board of Directors.

Members of the Compensation Committee:

Joseph C. Scodari (Chairman)

John J. Delucca

Nancy J. Hutson, Ph.D.

David B. Nash, M.D., M.B.A.

William F. Spengler

Table of Contents**Compensation Discussion and Analysis****Executive Summary**

This section (the CD&A) describes how Endo's compensation programs are designed for our NEOs and how the Company's compensation philosophy aligns with our underlying business objectives and strategies. This Executive Summary is intended to highlight key elements described in greater detail throughout the CD&A.

The Company made significant progress in the development and implementation of the long-term vision for the business and progress in realizing value creation. Our business was broadly diversified with the acquisition of American Medical Systems (AMS), a leader in urology medical devices, in June 2011, realizing \$300 million in 2011 revenue for Endo. In addition, the Company acquired the two leading urology healthcare information technology businesses, critical in executing the Company's total solutions strategy and essential to creating critical mass around a single health information and practice outcomes management platform. Along with the HealthTronics and Qualitest acquisitions, completed in 2010, we believe the Company has a highly diversified and sustainable revenue stream.

The Company also achieved strong operating results in 2011. Notably, exceptional financial results were realized. Net revenues were \$2.730 billion, with strong growth in all businesses and a June closing of the AMS transaction, representing nearly a 60% increase compared to 2010. The Company also achieved adjusted diluted EPS of \$4.69, a 35% increase versus 2010. Significant progress was made in the development of the product pipeline. The Company received approval for FORTESTA® Gel and commercially launched the product for men with low testosterone. The new formulation of OPANA® ER, designed to be crush-resistant, was approved and is planned for commercial launch in the second calendar quarter of 2012. Further, other important programs in branded pharmaceuticals were advanced and planned Abbreviated New Drug Application (or ANDA) filings were completed in the generics business, gaining a significant number of new product approvals. In medical devices, the Company advanced novel Endo concepts into development in urinary incontinence, prostate BPH and stone management, with significant new product assets acquired in the AMS merger.

- 1 Adjusted diluted EPS is not prepared in accordance with U.S. generally accepted accounting principles (GAAP) and may be different from non-GAAP financial measures used by other companies. Endo refers to this non-GAAP financial measure in making operating decisions because it believes it provides meaningful supplemental information regarding the Company's operational performance. For instance, Endo believes that adjusted diluted EPS facilitates its internal comparisons to its historical operating results and comparisons to competitors' results. The Company includes adjusted diluted EPS in its earnings announcements because it believes it is useful to investors in allowing for greater transparency related to supplemental information used by Endo in its financial and operational decision-making. In addition, Endo has historically reported similar non-GAAP financial measures to its investors and believes that the inclusion of comparative numbers provides consistency in its financial reporting at this time. Further, Endo believes that adjusted diluted EPS may be useful to investors as it is aware that certain of its significant stockholders utilize this measure to evaluate its financial performance. Finally, adjusted diluted EPS is considered by the Compensation Committee of Endo's Board of Directors in assessing the performance and compensation of substantially all of its employees, including its executive officers. Investors are encouraged to review the following reconciliation of adjusted diluted EPS to its most directly comparable GAAP financial measure—diluted EPS.

	2011	2010	2009
Adjusted diluted EPS	\$ 4.69	\$ 3.48	\$ 2.84
Upfront and milestone payments to partners	\$ (0.23)	\$ (0.20)	\$ (0.65)
Acquisition-related items, net	\$ (0.28)	\$ (0.16)	\$ 0.79
Cost reduction initiatives	\$ (0.18)	\$ (0.15)	\$ (0.02)
Asset impairment charges	\$ (0.96)	\$ (0.30)	\$ (0.59)
Amortization of intangible assets related to marketed products and customer relationships	\$ (1.57)	\$ (0.71)	\$ (0.53)
Inventory step-up	\$ (0.41)	\$ (0.05)	\$ (0.10)

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

Non-cash interest expense	\$	(0.16)	\$	(0.14)	\$	(0.12)
(Loss) gain on extinguishment of debt, net	\$	(0.10)	\$	-	\$	0.03
Accrual for unfavorable court decision for litigation	\$	(0.09)	\$	-	\$	-
Other income (expense), net	\$	0.02	\$	-	\$	0.03
Income tax	\$	0.82	\$	0.43	\$	0.59
Diluted EPS	\$	1.55	\$	2.20	\$	2.27

Table of Contents

— Compensation Philosophy

Endo's compensation philosophy is to pay for performance. The Compensation Committee believes that the most effective executive compensation program is one that is designed to provide incentives that advance the interests of shareholders and deliver levels of compensation that are commensurate with performance. Endo's compensation philosophy is designed to support our business strategy by attracting and retaining highly-talented individuals and motivating them to achieve competitive corporate performance, while embracing the Company's values and leadership attributes.

— Our executive compensation program seeks to:

- Create long-term shareholder value;
- Link compensation with company and individual performance;
- Rewarding high performance as measured against the company's strategic and business plans;
- Provide appropriate compensation for achieving annual results while fostering a long-term performance orientation;
- Reflect the competitive market for talent; and
- Mitigate risk.

— Elements of Executive Compensation

The Company's compensation programs consist of elements designed to complement each other and reward achievement of short-term and long-term objectives tied to the Company's performance through the establishment and achievement of strategic operating metrics or as a function of the Company's total shareholder return. In support of our compensation philosophy, we have chosen selected metrics to align employee compensation, including compensation for the NEOs, to the Company's strategic operating results and business strategy. The three principal components of the Company's total compensation are base salary, annual cash incentive compensation and equity-based LTI compensation.

- Base Salary reflects job responsibilities, value to the Company and individual performance while also taking into consideration market competitiveness.
- Annual cash IC is a short-term program that reinforces the Company's pay-for-performance approach, rewarding the achievement of annual goals and objectives.
- LTI compensation provides an equity-based award that is performance-based. The objective of the program is to align compensation for NEOs over a multi-year period directly with the interests of shareholders of the Company by motivating and rewarding the creation and preservation of long-term shareholder value.

— Say-on-Pay Consideration

In establishing 2012 compensation, the Compensation Committee also considered the results of the most recent stockholder advisory vote on executive compensation (the say-on-pay vote) at our annual meeting of stockholders held in May 2011, where over 94% of the votes cast on the say-on-pay proposal were voted in favor of the proposal, and over 81% voted in favor of our Board's recommendation to conduct an advisory vote on executive compensation every year, rather than every two or three year intervals. The Compensation Committee believes these results affirm stockholder support for our executive compensation decisions and policies, and as such, the Compensation Committee did not implement any changes as a result of this vote. The Compensation Committee will continue to consider the results of future say-on-pay votes when making executive compensation decisions and policies.

Table of Contents

Compensation Committee Actions

In response to the evolving nature of our business structure and our goal to strengthen our executive pay practices, special emphasis has been placed on enhancing the effectiveness of our executive compensation decisions and policies. The following summarizes the actions taken by the Compensation Committee over the past two years:

Item	Actions Reported in 2011	Actions Reported in 2012
Competitive Considerations	Revised Data Point Companies to appropriately compare each NEO's total compensation to executives in similar positions and with similar responsibilities at similar companies of comparable size.	In response to the Company's recent acquisitions and changing business, Hay Group recommended a recalibration of the of the Data Point Companies to include a cross industry composite of organizations that reflect the Company's current business segments. As a result of this review, the Compensation Committee approved the Data Point Companies.
Performance-Based Annual Cash IC	<p>Initiated an annual performance management process setting clear financial, strategic, portfolio and organizational goals utilizing a well-defined scorecard that closely links pay and performance.</p> <p>Adopted a compensation recovery policy (clawback) relating to repayment of cash incentive awards by an executive in the event of a restatement of the Company's financial results; and</p> <p>Increased the level of performance required to reach minimum, target, and maximum payout levels.</p>	<p>Expanded annual performance management process setting clear financial, strategic, portfolio and organizational goals utilizing well-defined scorecards across the Company's various business segments that closely links pay and performance;</p> <p>Approved the Company's annual scorecard of objectives and metrics to reflect business conditions and the Company's strategy;</p> <p>Increased the level of performance required to reach minimum, target, and maximum payout levels; and</p> <p>Introduced profitability-based program funding criteria in addition to the financial metrics already included in the Company and business-level annual scorecards.</p>
Equity-Based LTI Compensation	<p>Moved from a single trigger to a double trigger change in control provision in our 2010 Stock Incentive Plan;</p> <p>Re-aligned the mix of the LTI awards to include performance share units that may be earned based on total stockholder return and revenue growth over a three-year period to continue aligning compensation with stockholder interests and the Company's performance; and</p> <p>Revised stock ownership guidelines for both non-employee Directors and for Executive Management to further align their interests with the interests of stockholders and promote Endo's commitment to sound corporate governance.</p>	<p>Revised the peer group used to measure relative total stockholder return performance for our performance share unit (PSU) awards, since the Standard and Poor's (S&P) 1500 Healthcare Index is more broadly representative of the overall healthcare environment in which the Company operates; and</p> <p>Increased the level of performance required to achieve minimum, target and maximum payout levels associated with the Company's PSU cumulative target net sales objectives.</p>
Employment		

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

Agreements

The Company has affirmatively determined not to offer new employees gross-up payments related to excise tax liabilities resulting from a change in control as demonstrated by the employment agreements entered into with Mr. Levin and Ms. McHugh.

The Company continued its practice of not offering new employees gross-up payments related to excise tax liabilities resulting from a change in control as demonstrated by the employment agreements entered into with Mr. Holveck and Dr. Gergel. Mr. Holveck's and Dr. Gergel's employment agreements were amended further to exclude automatic renewal provisions.

Pay Risk

Conducted risk analysis of compensation arrangements, policies and practices to determine whether the Company's compensation policies and practices create risks that are reasonably likely to have a material adverse effect on the Company.

Continued with the practice of conducting annual risk assessments of compensation arrangements, policies and practices.

Table of Contents

The Company's Executive Compensation Program

Overall Program Objectives

The Company's primary objective with respect to executive compensation is to design compensation programs that align executives' compensation with the Company's overall business strategies for the creation of stockholder value and attract, motivate and retain highly qualified executives. The Compensation Committee believes that the most effective executive compensation program is one that is designed to reward the achievement of specific annual, long-term and strategic goals of the Company, and which aligns executives' interests with those of the shareholders by rewarding performance in meeting or exceeding established goals, with the ultimate objective of improving shareholder value.

Accordingly, the Company provides incentives to advance the interests of shareholders and deliver levels of compensation that are commensurate with performance. Overall, the Company designs its compensation program to:

- create a strong performance alignment with shareholders' interests;
- support the corporate business strategy and business plan by clearly communicating what is expected of executives with respect to goals and results and by rewarding achievement; and
- recruit and retain superior executive talent.

The Company seeks to achieve these objectives through three key compensation elements:

- a base salary;
- a performance-based annual cash incentive (i.e., annual IC program); and
- an annual (and, under certain circumstances, periodic) grants of long-term, equity-based compensation (i.e., a long-term incentive), comprised of stock options, restricted stock units subject to time-based vesting requirements, and performance share units that have performance-based vesting requirements.

In order to enhance the Compensation Committee's ability to carry out its responsibilities effectively, as well as maintain strong links between executive pay and performance, the Compensation Committee reviews compensation information for each NEO which includes the following information:

- the annual compensation and benefit values that are being offered to each executive;
- the value of all outstanding equity awards; and
- the value of all other compensation.

The Compensation Committee also meets with our Chairman, President and Chief Executive Officer and other senior management in connection with compensation matters and regularly meets in executive sessions with and without Hay Group Compensation Committee consultants.

Competitive Considerations

In making compensation decisions with respect to each element of compensation, the Compensation Committee considers the competitive market for executives and compensation levels provided by comparable companies. The Compensation Committee regularly reviews the compensation practices at companies with which it competes for talent, including businesses engaged in activities similar to those of the Company, including branded pharmaceuticals, generics, devices and services. While we do not believe that it is appropriate to establish compensation levels based primarily on benchmarking, we believe that information regarding pay practices at other companies is nevertheless useful in two respects. First, we recognize that our compensation practices must be competitive in the marketplace. Second, independent marketplace information is one of the many factors that we consider in assessing the reasonableness of compensation.

The Compensation Committee generally targets total executive compensation at the median of compensation packages for executives in similar positions and with similar responsibilities and experience at similar companies of comparable size with the opportunity for top quartile compensation based upon individual and company performance. We recognize, however, that positions with similar titles at the Data Point Companies are not always comparable in terms of responsibility to such positions at the Company. The Compensation Committee's choice of this target percentile reflects the Company's consideration for our shareholders' interests in paying what is competitive, but not significantly more than that which is competitive, to achieve our corporate goals, while conserving cash and equity as much as practicable.

We believe that, given the industries in which we operate and our compensation philosophy and objectives, compensation targeted at the median of similar companies with the opportunity for top quartile total compensation based upon performance is generally sufficient to retain our current executive officers and to hire new executive officers when and as required. In setting compensation for the NEOs, the Compensation Committee considers comparative market data requested from Hay Group, its compensation consultant. In gathering relevant competitive market compensation data, the Compensation Committee approved the use of a sample of mid-sized companies with similar operations as Endo.

Table of Contents

We refer to all of these sample companies as the Data Point Companies. The Committee believes that Endo competes with the Data Point Companies for talent and for shareholder investment. The Data Point Companies typically have similar executive officer positions and create a range of comparative compensation values that are utilized by the Compensation Committee to confirm that salary levels and overall incentive opportunities approved by the Compensation Committee are consistent with the Company's overall objectives. In response to the Company's recent acquisitions and changing business, Hay Group recommended a recalibration of the of the Data Point Companies to include a cross industry composite of organizations that reflect the Company's current business segments. As a result of this review, the Compensation Committee approved the Data Point Companies in 2011 listed in the table below.

2011 Data Point Companies			
Allergan Inc.	Celgene Corporation	Intuitive Surgical, Inc.	Salix Pharmaceuticals Ltd.
Biogen Idec Inc.	Edwards Lifesciences Corporation	Medicis Pharmaceutical Corporation	Valeant Pharmaceuticals Inc.
C.R. Bard, Inc.	Forest Laboratories Inc.	Mylan Inc.	Warner Chilcott Ltd.
CareFusion Corporation	Gilead Sciences, Inc.	Par Pharmaceuticals	Watson Pharmaceuticals Inc.

From time to time, the Compensation Committee re-evaluates the Data Point Companies from a business revenue allocation perspective once any respective segment shifts by +/- 15%. Accordingly, the Data Point Companies may change, as was the case in 2011. The graphs below reflect the Data Point Companies' revenue composition for the most recent fiscal year at the time of the Compensation Committee's approval in 2011, as well as Endo's actual revenue allocation across business segments for 2011.

The Compensation Committee does not attempt to set each compensation element for each executive within a particular range related to levels provided by the Data Point Companies. Instead, the Compensation Committee uses market comparisons as one factor in making compensation decisions. Other factors considered when making individual executive compensation decisions include individual contribution and performance, reporting structure, complexity and importance of role and responsibilities, leadership and growth potential.

In establishing 2012 compensation, the Compensation Committee also considered the results of the most recent stockholder advisory vote on executive compensation (the say-on-pay vote) at our annual meeting of stockholders held in May 2011, where a substantial majority of the votes cast on the say-on-pay proposal were voted in favor of the proposal. The Compensation Committee believes these results affirm stockholder support for our executive compensation decisions and policies, and as such, the Compensation Committee did not implement any changes as a result of this vote. The Compensation Committee will continue to consider the results of future say-on-pay votes when making executive compensation decisions and policies.

Table of Contents

Pay Risk

At least on an annual basis, the Company's management team conducts an assessment of the potential risks associated with the Company's compensation arrangements, policies and practices. The assessments are then reviewed by the Company's Compensation Committee. A key objective is to determine whether the Company's compensation policies and practices create risks that are reasonably likely to have a material adverse effect on the Company. This risk assessment process includes:

- A comprehensive review of compensation programs with the highest potential for material adverse effect;
- Identification of key Company positions and business areas that could potentially carry a significant portion of the Company's risk profile;
- Identification of compensation programs for the key Company positions and/or business areas;
- An analysis of employee compensation plans with the highest potential for risk pursuant to which we:
 - ┆ Identify the features within the plans that could potentially encourage excessive or imprudent risk taking;
 - ┆ Identify business risks that these features could potentially encourage;
 - ┆ Identify controls and plan features that mitigate the risks identified;
 - ┆ Determine residual risk remaining after having identified mitigating controls and features; and
 - ┆ Assess whether residual risk is reasonably likely to have a material adverse effect on the Company as a whole.

When reviewing the Company's compensation programs, particular attention is paid to programs that allow for variable payouts and consider whether there is the proper mix of performance metrics and that the plans reward both annual goal achievement and the long-term sustainable success of the Company. In addition, the reviews focus on plans where an employee might be able to influence payout factors and programs that involve our executives, with a focus on analyzing whether any of the performance targets encourage excessive risk taking. During the assessments, several control and design features of the Company's compensation program that are intended to mitigate the risk of excessive risk-taking are evaluated.

Based on the process described above, it was concluded that the potential risks associated with the Company's compensation policies and practices are not reasonably likely to have a material adverse effect on Endo. Management will continue to review the Company's compensation programs at least annually to identify and address potential risks that may have a material adverse effect on the Company.

Compensation Components

The three principal components of the Company's total compensation are: base salary, annual cash incentive compensation and equity-based LTI compensation. In allocating compensation among these elements, we believe that the majority of the compensation of our senior-most levels of management—the levels of management having the greatest ability to influence the Company's performance—should be performance-based, while lower levels of management should receive a greater portion of their compensation in base salary.

In making decisions with respect to any element of a named executive officer's compensation, the Compensation Committee considers the total compensation that may be awarded to the officer, including salary, annual IC cash bonus and long-term incentive compensation. In addition, in reviewing and approving employment agreements for NEOs, the Compensation Committee considers the other benefits to which the officer is entitled by the agreement, including compensation payable upon termination of the agreement under a variety of circumstances. The Compensation Committee's goal is to award compensation that is competitive to attract and retain highly qualified leaders and motivate high business performance. The Compensation Committee believes that its compensation programs align executive and shareholder interests as well as vary compensation based on individual and Company performance.

Base Salary

Purpose. The objective of base salary is to reflect job responsibilities, value to the Company and individual performance while taking into consideration market competitiveness. We seek to provide our executive officers with competitive annual base salaries in order to attract and retain them. The base salary component of our executive officer compensation program is not designed to incentivize our near-term performance (as performance-based cash bonuses are designed to do), but rather to provide the baseline level of compensation to executive officers.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

Considerations. Salaries for the NEOs are determined initially by each individual's employment agreement which are described under "Employment Agreements" below. These salaries and the amount of any increase over these salaries are determined by the Compensation Committee based on a variety of factors, including:

the nature and responsibility of the position and, to the extent available, salary norms for persons in comparable positions at the Data Point Companies;

Table of Contents

- the expertise and competencies of the individual executive;
- the competitiveness of the market for the executive's services;
- internal review of the executive's compensation, both individually and relative to other NEOs;
- the recommendations of the President and Chief Executive Officer (except in the case of the President and Chief Executive Officer's own compensation); and
- individual performance of the NEO, which includes:
 - i achievement of individual annual goals and objectives, the risks and challenges involved, and the impact of the results;
 - i performance of day-to-day responsibilities;
 - i increases in competencies and skill development;
 - i value of their contribution to function and company goal achievement; and
 - i behaviors aligned with Endo core values.

Base salaries are generally reviewed annually. In reviewing salaries, the Compensation Committee adjusts salaries from time to time to realign salaries with market levels, individual performance and incumbent experience. The Compensation Committee also considers salaries relative to those of others within the Company and may, on occasion, make adjustments to salaries or other elements of total compensation, such as incentive compensation and long-term incentive opportunities, where such an adjustment would correct a compensation imbalance, as the Compensation Committee deems appropriate.

2011 Decisions Regarding Base Salary. In December 2011, as part of the Compensation Committee's annual review of compensation, Hay Group provided the Compensation Committee with a market assessment of the competitive compensation for the Company's executive officers. This assessment included reviewing the Data Point Companies and:

- establishing a benchmark match for each of the positions;
- gathering and analyzing competitive compensation from relevant labor markets; and
- developing competitive market medians of compensation for the positions.

Based on the competitive market data referred to above, the Compensation Committee developed, with the assistance of Hay Group, market medians of compensation for each of Endo's compensation elements (base salary, target annual incentive compensation, and expected value of long-term incentive compensation) and then compared each NEO's current compensation to the market median for each data sample. The market data and the performance of each of Endo's NEOs are reviewed each year, but there is no guarantee that any of their individual compensation packages will be aligned with the market. Please reference Individual Compensation Determination section below for approved salary actions.

Performance-Based Annual Cash Incentive Compensation (IC)

Purpose. The compensation program provides for an annual cash incentive that reinforces the Company's pay-for-performance approach. This incentive compensation, or IC, program is a short-term performance-based incentive plan that rewards achievement of annual goals and objectives. The objective of the program is to compensate individuals based on the achievement of specific goals that are intended to correlate closely with shareholder value.

The respective annual cash IC target for each named executive officer related to 2011, to be paid in early 2012, is expressed in the graph to the right.

Considerations. The annual cash IC program includes relative incentive levels based on the NEO's accountabilities, performance objectives and impact on Company operations, with target award opportunities established as a percentage of base salary. Each NEO's target IC bonus is established pursuant to their respective employment agreement, which is determined based on all factors that the Compensation Committee deems relevant, including (but not limited to) a review of the Data Point Companies' compensation. The annual bonus process for our NEOs involves two basic steps:

- At the outset of the year:
 - i Set overall Company performance goals using a disciplined scorecard process; and
 - i Set individual objectives aligned with the business strategy and Company scorecard for the year.
- At the end of the year:
 - i Measure actual performance (individual and Company-wide) against the predetermined Company performance goals and individual performance measures to determine the appropriate award.

Table of Contents

These two steps are further described below:

- (1) **Setting Company performance goals.** Early in each year, the Compensation Committee, working with senior management, sets performance goals for the Company. The bonus determination for each NEO was primarily based upon the Company's performance against these goals. The goals that were established for 2011 are discussed below under **2011 Decisions Regarding Incentive Compensation**. In determining the extent to which the pre-set performance goals are met for a given period, the Compensation Committee exercises its judgment whether to reflect or exclude the impact of changes in accounting principles and extraordinary, unusual or infrequently occurring events reported in the Company's public filings.
- (2) **Measuring performance.** After the end of the year, the Compensation Committee reviews the Company's actual performance against each of the performance goals established at the outset of the year. The Compensation Committee assesses the Company's performance as well as each NEO's performance against the individual goals set at the outset of the year. This assessment allows bonus decisions to take into account overall Company performance and each NEO's personal performance and contribution during the year.

Discretion. Under the IC program, the Compensation Committee has discretion, in appropriate circumstances (e.g., should the individual's performance in any particular year be evaluated as outstanding), to pay incentive compensation at less than or in excess of target levels, but no more than the lesser of 1) the maximum aggregate amount of the annual incentive pool based on a pre-established fixed percentage of consolidated adjusted net income or 2) a maximum individual amount of \$3,000,000 for the President and Chief Executive Officer and three other highest-paid executive officers (not including the Company's Executive Vice President & Chief Financial Officer), which is the amount approved by shareholders in accordance with IRC 162(m) of the Internal Revenue Code under Endo's 2010 Stock Incentive Plan. Further, pursuant to each of our NEOs' employment agreements, target IC as a percentage of annual base salary may subsequently be increased at the discretion of the Compensation Committee. Accordingly, in February 2011, as presented for consideration to the Compensation Committee by Hay Group following an analysis showing competitive Chief Executive Officer compensation among the Data Point Companies, as well as the position of the President and Chief Executive Officer in relation to other senior company executives, the Compensation Committee increased Mr. Holveck's IC target from 100% to 120% of his annual base salary, which was reflected in the IC payments related to 2011 that were paid in early 2012.

2011 Decisions Regarding Incentive Compensation. The following information summarizes the components of the Company's IC program and the basis for the actual award granted by the Compensation Committee for 2011. With respect to 2011, the annual award to each of the NEOs was based on the achievement of corporate goals as well as each NEO's individual performance and demonstrated leadership. The Compensation Committee established corporate performance goals for 2011, placing emphasis on the Company's most important strategic and operating objectives. For 2011, the IC weightings were recalibrated to place additional emphasis on business development and integration activities. The performance goals were weighted as follows (specific targets are discussed in the following section heading **2011 Company Performance Against Objectives**):

The above scorecard is calibrated so that results will generally range between 50% and 150% of target award opportunity, commensurate with performance. The stretch (150%) and threshold (50%) goals are set so that the Company's financial performance achieved in each scenario will appropriately fund the cost of the cash incentives. The Compensation Committee, however, has the discretion to withhold annual cash incentives that otherwise would be made to any employees, including the NEOs, if it determines, either on a quantitative or a qualitative basis, that overall performance is too low. Moreover, the scorecard achievements are assessed based on whether the Company achieved the scorecard results considering (1) current healthcare compliance as reflected by a robust internal compliance program and as determined by outcomes of regulatory review and inspections, such as those of the Food and Drug Administration, and (2) progress on health and safety outcomes as determined by other regulatory and environmental matters.

Table of Contents

2011 Company Performance Against Objectives. Despite the continued challenges in the economic environment in 2011, the Company significantly exceeded the target goals for 2011 set by the Compensation Committee for annual incentives. The numbers in the graph below are in millions, other than per share information.

Financial Objectives:

- ¡ Achieved significant diversification of revenue stream, as well as substantially enhanced earnings and cash flow required to reduce debt;
- ¡ Achieved net revenues in 2011 of \$2.730 billion, representing a 59% increase compared to 2010; and
- ¡ Achieved adjusted diluted EPS of \$4.69, representing a 35% increase versus 2010.

- 1 See discussion about adjusted diluted EPS and a reconciliation to its most directly comparable GAAP financial measure in the Executive Summary above.

Strategic Achievement:

- ¡ Substantial progress achieved in transforming the business through strategic transactions and organic growth, and in building a broad base of products and services to improve access, outcomes and economics;
- ¡ Continued success with our strategy to diversify the Company’s revenue stream in creating a sustainable growth business, substantially reducing the Company’s reliance on LIDODER[®];
- ¡ Further strategically diversified the business to now incorporate offerings in mobile and health information technology services, and product offerings in drugs, devices, drug-devices and diagnostics;
- ¡ Completed acquisition of American Medical Systems (AMS), the leader in urology medical devices, furthering the Company’s strategy as total solutions provider;
- ¡ Completed Intuitive Medical Software, LLC and meridianEMR, Inc. acquisitions essential to creating critical mass around a single health information and practice outcomes management platform; and
- ¡ Demonstrated substantial progress in strategy execution through the creation of commercially driven acquisition-enabled revenue streams and the implementation of cost synergies across business segments, contributing to debt reduction and shareholder value (stock price appreciation) commitments.

Portfolio Development:

- ¡ Following the approval of FORTESTA[®] Gel, commercially launched the product for men with low testosterone;
- ¡ Obtained U.S. Food and Drug Administration (FDA) approval for new formulation of OPANA[®] ER designed to be crush-resistant, addressing the growing demand for improved opioid formulations;
- ¡ Progressed key development assets through regulatory processes;
- ¡ Continued advancement of discovery programs in oncology, urology and pain;
- ¡ Completed planned generics ANDA filings while gaining a significant number of new product approvals; and
- ¡ Expanded the devices product pipeline with several new urology programs now in development as well as initial new product concepts generated in collaboration with partners.

Table of Contents

Organization Advancement:

- i Successfully integrated Qualitest and AMS into Endo, retaining key talent while initiating cross-selling pilots as initial steps to realize total solutions strategy;
- i Following the AMS acquisition, completed cost assessment and identified cost-saving opportunities in all functional areas;
- i Implemented quality and compliance controls for acquired businesses and new business initiatives;
- i Enhanced the Company’s leadership capabilities and critical position succession with the completion of several key executive hires;
- i Further strengthened the Company’s culture by integrating a set of leadership attributes into talent management processes; and
- i Augmented organization capabilities and the leadership talent pipeline through targeted development of key leaders and the retention of senior talent who joined Endo through acquisitions.

The performance goals are established to be challenging and ambitious, but also realistic enough to be reasonably attainable given a concerted effort on the part of the Company’s NEOs and employees in consideration of conditions and trends. In the past three years the NEOs achieved performance goals above target, at target or slightly below target levels. For 2011, a 118% incentive pool was achieved and awarded by the Compensation Committee for the NEOs.

The Compensation Committee reviewed the Company’s achievement of the financial and other objectives set forth above as well as each named executive officer’s contributions and awarded the NEOs the bonus amounts set forth in the Summary Compensation Table.

See also below under the heading “Post-Termination Benefit” regarding how each named executive officer with an employment agreement will be entitled to cash incentive compensation as a percentage of salary.

Equity-Based Long-term Incentive (LTI) Compensation

Purpose. The LTI program provides an annual award (and, under certain circumstances, a periodic award) that is performance-based. The objective of the program is to align compensation for NEOs over a multi-year period directly with the interests of shareholders of the Company by motivating and rewarding creation and preservation of long-term shareholder value. The level of LTI compensation is determined based on an evaluation of competitive factors in conjunction with total compensation provided to NEOs and the goals of the compensation program described above. Currently, LTI awards are equity-based and provide for the awarding of stock options, PSUs and restricted stock units (RSUs). The timing of our equity grants, including stock options, is not coordinated in a manner that intentionally benefits our executive officers or coincides with the release of material non-public information.

The Company believes that a combination of stock options, PSUs and RSUs closely equates the value of the benefit received by the recipient to the accounting expense of the benefit to the Company. The Company also believes that the resulting blend of options, PSUs and RSUs will more accurately reflect the pattern of equity-based awards that prevails in the Data Point Companies and in the external market generally. For 2012 grants, the targeted LTI mix of options, PSUs and RSUs for senior management is reflected in the graph to the left.

In determining the annual LTI grants for the NEOs, the Compensation Committee considered any pre-existing contractual requirements, market data on total compensation packages, the value of long-term incentive grants at the Data Point Companies, total shareholder return, share usage and shareholder dilution and, except in the case of the award to the President and Chief Executive Officer, the recommendations of the President and Chief Executive Officer.

Table of Contents

The respective equity-based LTI compensation target for each named executive officer related to 2011, to be paid in early 2012, is reflected in the graph to the right.

Further, Company and individual performance are considered in the awarding of annual equity-based compensation to NEOs:

Overall Company results versus Performance Scorecard. Company performance is measured as described above in the Assessment of Performance-Based Annual Incentive Compensation. Annual goals were set in four categories, financial objectives, strategic achievement, portfolio development and organization advancement objectives. At the end of the performance year, an assessment is made of Company results versus pre-determined objectives.

Individual performance determined by assessing each named executive officer's achievements versus annual performance objectives. Regarding individual performance, each named executive officer has annual performance objectives that contribute to the growth and development of the Company. At the end of the performance year, each named executive officer is assessed and given an overall performance rating. The final rating is then factored into the awarding of equity-based compensation.

Based upon the achievement of Company goals and individual objectives, our President and Chief Executive Officer recommends an adjustment to each named executive officer's target annual equity-based LTI compensation target based upon performance related to key job accountabilities and annual performance objectives. The recommendation is then reviewed by the Compensation Committee, which has discretion to modify the final award. Regarding the award for the Company's President and Chief Executive Officer, the Compensation Committee follows a similar process and has the ultimate discretion for determining the annual equity award.

Discretion. Mr. Holveck's employment agreement does not prescribe a specific LTI target but instead provides that his LTI compensation will be determined at the sole discretion of the Compensation Committee if the Company and executive achieve certain performance targets set by the Committee with respect to each year ending during Mr. Holveck's employment term. All other NEOs are eligible to receive LTI compensation in an amount equal to a fixed percentage of their annual base salary for such year (or such lesser (including zero) or greater percent of the base salary for such year as is recommended to the Compensation Committee by the CEO and approved by the Compensation Committee).

Stock Options. The Company's LTI compensation has historically taken the form of stock option awards. Stock options reward NEOs only if the stock price increases.

The LTI program calls for stock options to be granted with exercise prices of not less than the closing price of our common stock as quoted on the NASDAQ on the date of grant and generally to vest ratably over four years based on continued employment. The Compensation Committee will not reduce the exercise price of stock options (except in connection with adjustments to reflect recapitalizations, stock or extraordinary dividends, stock splits, mergers, spin-offs and similar events permitted by the relevant plan) without shareholder approval. New option grants to NEOs normally have a term of ten years.

Performance Share Units. Beginning in 2010, PSU awards were and now continue to be granted annually, with each award covering a three-year performance period. Through this program, senior leaders are eligible to earn a specified target number of shares of Company stock at the end of the three-year performance period. The actual stock award is paid out at the end of the three-year plan period depending on how well the Company performed against the targets set at the beginning of the three-year program. This portion of the Company's LTI program focuses the Company's leaders on delivering business performance over the next three years against certain key financial metrics that are designed to drive long-term shareholder value as defined in each year's performance award agreements. Specifically, for PSUs granted in 2010 and 2011, the payouts are made in shares of common stock, with the actual number of shares awarded dependent upon:

the Company's total shareholder return (TSR) performance over the performance period relative to the total shareholder return performance of the NASDAQ Biotechnology Index (the TSR Stock Award); and cumulative net sales over the performance period (the Net Sales Stock Award).

Table of Contents

For PSUs granted in 2012, TSR performance will be measured relative to the S&P 1500 Health Care Index instead of the NASDAQ Biotechnology Index, reflecting our continuing transition to a broader healthcare solutions company.

The number of PSUs awarded to each executive is based on a targeted percentage of the executive's base salary with the actual number of shares awarded adjusted to between zero and 200% of the target award amount based upon achievement of pre-determined TSR performance and cumulative net sales goals. PSUs are designed to encourage and reward our executives for achieving longer-term financial goals as well as meeting or exceeding the relative financial performance of our industry group.

In February 2012, the Compensation Committee reviewed and approved measures and target performance levels for the 2012-2014 performance period and awarded PSUs to its NEOs. The performance period for these awards began on January 1, 2012 and ends on December 31, 2014. Payouts with respect to these PSUs, if any, will be made in shares of Company common stock in February 2015, following the close of the three-year performance cycle. In determining the extent to which the pre-set performance measures are met for a given period, the Compensation Committee may exercise its judgment whether to reflect or exclude the impact of changes in accounting principles and extraordinary, unusual or infrequently occurring events reported in the Company's public filings.

Holders of PSUs will be entitled to receive a number of shares of Company common stock as of December 31, 2014 equal to a multiple of the TSR Stock Award based on the Company's relative Total Shareholder Return (as specifically defined below) for the performance period as compared to the Total Shareholder Return for the performance period of companies comprising the S&P 1500 Health Care Index as of the last day of the performance period, in accordance with the graph to the left; provided, however, that, notwithstanding the graph to the left, no portion of the TSR Stock Award shall vest if the Company's Total Shareholder Return for the performance period is negative.

Total Shareholder Return shall mean the appreciation of the Per Share Price during the performance period, plus any dividends paid on the applicable company's common stock during such performance period.

Per Share Price shall mean the average of the closing prices of common shares for the applicable company during the eighty (80) consecutive trading days ending on the day prior to the applicable measurement date.

Holders of PSUs will be entitled to receive a number of shares of Company common stock as of December 31, 2014 equal to a multiple of the Net Sales Stock Award based on the Company's cumulative Net Sales (as specifically defined below) for the performance period as compared to the Company's target Net Sales in accordance with the graph to the right.

In setting the Company's cumulative Net Sales target, the Compensation Committee considers several factors, including the Company's three-year organic sales growth projections, new product introductions, and incremental revenues associated with new business opportunities. For any payout to occur for the portion of the program related

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

to cumulative Net Sales, significant Net Sales growth must be achieved relative to the actual Net Sales for the year preceding the performance period.

Net Sales shall mean the revenues from the Company's sales (including, but not limited to, sales of the Company's pharmaceutical products, devices and services) plus royalties and other payments earned from third parties as a result of licensing activities and royalties earned on sales of the underlying products, as recognized in accordance with accounting

Table of Contents

principles generally accepted in the United States (or another basis of accounting, such as International Financial Reporting Standards, should the Company adopt or be required to adopt another basis of accounting).

The determination of Total Shareholder Return and Net Sales will be made in the sole discretion of Board. The Board also has discretion to accelerate the vesting of all or a portion of the Participant's Performance Award based upon the overall performance of the Company and/or the Participant or based upon any change in business conditions, provided that the exercise of such discretion would not cause a Performance Award that would otherwise be deductible as performance-based compensation within the meaning of Section 162(m) of the Code to become non-deductible.

Restricted Stock Units. In addition to the stock options and PSUs described above, our NEOs also are granted time-based RSUs, which are the third element of our equity-based LTI compensation package. RSUs are valued based on the closing price of our common stock on the NASDAQ on the date of grant, and each RSU represents the right to receive one (1) share of Company common stock as of the date of vesting. RSUs granted to the NEOs, generally vest ratably over four years based on continued employment.

Considerations. The Company believes that the most effective means to encourage long-term performance by our NEOs is to create an ownership culture. This philosophy is implemented through the granting of the equity-based awards described above. The LTI program described above is designed so that Company leaders hold a competitive stake in the Company's financial future. The LTI program provides a future reward structure so that employees who have an impact on the Company's performance share in the results of that impact. The LTI pool is established annually based on the Company's achievement of goals and objectives, and can vary significantly from year to year. Prior to changing eligibility requirements in 2011, which generally establishes eligibility at the manager-equivalent level, all Company employees were previously eligible to receive LTI. While these reductions in eligibility were implemented to more closely align Company and industry practices, the introduction of the approved Employee Stock Purchase Plan (ESPP) in 2012 reinforced the Company's emphasis on building an ownership culture. LTI opportunities remain an important component of the Company's compensation philosophy, and are allocated most heavily to:

- Reward consistently high performing individuals who we expect will drive the future value of the Company;
- Reward individuals at various levels who have high impact relative to the expectations of their role; and
- Retain eligible individuals who have skills critical to the long-term success of the Company and who exemplify our core value behavior.

Timing of Grants. Annual grants of stock options, PSUs and RSUs to our NEOs are made at a regularly scheduled meeting of the Board of Directors held during the first quarter of each year, and the grant date is the date of that meeting. The Compensation Committee may also make occasional grants during the year to employees of the Company. These grants are typically associated with promotions and hiring, and are typically made on the effective date of the promotion or the first day of work.

2011 Decisions Regarding Equity-Based LTI Program. In 2011, the Compensation Committee awarded LTI compensation for NEOs pursuant to the program described above resulting in the awards of stock options and restricted stock units identified in the Summary Compensation Table and the 2011 Grants of Plan-Based Awards Table.

Periodic Review. The Compensation Committee reviews both the annual IC program and the LTI program annually to confirm that their key elements continue to meet the objectives described above.

Ownership Guidelines for Executive Management. The Ownership Guidelines approved on December 10, 2011 currently advise that Executive Management should, but is not required to, have an ownership equal in value as follows:

Executive Management is expected to achieve the Ownership Guidelines within five (5) years of joining the Company, or, if in the case of individuals serving in this capacity at the time the Ownership Guidelines were adopted, within five (5) years of the date of adoption of the Ownership Guidelines. Executive Management is also expected to continuously own sufficient shares to meet the Ownership Guidelines once attained. Members of Executive Management who subsequently get promoted to a higher level will have five years from the date of promotion to achieve their new ownership target.

Table of Contents**Individual Compensation Determination**

Under our compensation structure, the mix of base salary, cash IC and equity-based LTI compensation varies depending on each named executive officer's level. Although the Company has no pre-established policy or target for the allocation between either cash and non-cash or short-term and long-term incentive compensation, the following summarizes the incentive compensation decisions for the current named executive officers based on 2011 performance:

Name	Base Salary as of December 31, 2011	2011 IC Target	2011 IC Actual	2011 Long-Term Equity Incentive Compensation Target	2011 Long-Term Equity Incentive Compensation Actual
David P. Holveck	\$ 1,100,000	\$ 1,320,000	\$ 1,869,120	\$ 4,400,000	\$ 5,500,000
Alan G. Levin	\$ 643,000	\$ 353,650	\$ 563,364	\$ 1,286,000	\$ 1,736,100
Julie H. McHugh	\$ 560,000	\$ 336,000	\$ 475,776	\$ 1,400,000	\$ 1,680,000
Ivan P. Gergel, M.D.	\$ 636,000	\$ 349,800	\$ 412,764	\$ 1,272,000	\$ 1,399,200
Caroline B. Manogue	\$ 540,000	\$ 297,000	\$ 438,075	\$ 1,080,000	\$ 1,350,000

Each named executive officer's target percentage and actual number of stock options, PSUs, and RSUs granted in 2012 based on 2011 performance were as follows:

Name	LTI Target % of Base Salary	Options Actually Granted	PSUs Actually Granted	RSUs Actually Granted
	David P. Holveck	400%	173,940	52,834
Alan G. Levin	200%	54,905	16,677	16,677
Julie H. McHugh	250%	53,131	16,138	16,138
Ivan P. Gergel, M.D.	200%	44,250	13,441	13,441
Caroline B. Manogue	200%	42,694	12,968	12,968

David P. Holveck**President and Chief Executive Officer**

To provide further assurance of independence, the compensation recommendation for the President and Chief Executive Officer is developed by Hay Group, the Committee's independent consultant. Hay Group prepares analyses showing competitive Chief Executive Officer compensation among the Data Point Companies for the individual elements of compensation and total direct compensation. The consultant develops a range of recommendations, based on various company and individual performance assumptions, for any change in the President and Chief Executive Officer's base salary, annual cash incentive, equity grant value, and equity mix. The recommendations take into account the competitive Data Point Company pay analysis, expected future pay trends, and the position of the President and Chief Executive Officer in relation to other senior company executives and proposed pay actions for all key employees of the Company. The range allows the Committee to exercise its discretion based on the President and Chief Executive Officer's individual performance and other factors. The results of this analysis are shared with the Committee, during which time the Company's performance, and the performance of the President and Chief Executive Officer are evaluated, and compensation decisions determined. The President and Chief Executive Officer has no prior knowledge of the recommendations, and only participates in the process during the stage when he reviews his evaluation of Company performance and his personal performance with the Committee. The President and Chief Executive Officer takes no part in the recommendations, Committee discussions, or decisions, other than what is described above. The Board's assessment of Mr. Holveck's performance is based primarily on the development and execution of a long-term

vision for the Company and the evaluation of company operating and financial performance as summarized on pages 24-26.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

Based on the Company's strong overall results, an evaluation of Mr. Holveck's individual performance, and an analysis of the competitiveness of his pay related to the Company's Data Point Companies conducted by the Compensation Committee's consultant, Hay Group, Mr. Holveck's base compensation was increased to \$1,155,000 effective March 1, 2012. Further, Mr. Holveck was awarded an annual performance-based bonus equal to 141.6% of his target amount and an equity award equal to 125% of his target.

Alan G. Levin

Executive Vice President & Chief Financial Officer

Mr. Levin serves as Chief Financial Officer, and is also responsible for investor relations and business development. Mr. Levin exhibited strong financial leadership in 2011, as evidenced by the Company exceeding key financial targets, including revenue and EPS, while managing operating income, cash flows and debt obligations. Among his many accomplishments in 2011, Mr. Levin led the execution of the Company's business development and capital markets strategies resulting in three key acquisitions in 2011, including AMS, Intuitive Medical Software, LLC and me-ridianEMR, Inc. Mr. Levin also played a critical role in the integration of the acquired companies into Endo which involved the planning and executing the financial structure of the combined company, while identifying enterprise-wide savings opportunity in the general and administrative functions. Based on Mr. Levin's leadership of critical business functions and his contributions to the Company's accomplishments

Table of Contents

in 2011, he received a merit increase of 4.2% effective March 1, 2012. Further, Mr. Levin was awarded an annual performance bonus equal to 159.3% of his target and an equity award equal to 135% of his target.

Julie H. McHugh

Chief Operating Officer

Ms. McHugh is responsible for developing and executing the Company's operational and strategic commercial objectives, and is accountable for leading enterprise-wide information technology solutions. Ms. McHugh has substantially improved the Company's operational execution by aligning all commercial units with the Company's total healthcare solutions strategy and creating commercially driven acquisition-enabled revenue streams. Ms. McHugh contributed significantly to the execution of the Company's business development strategy, participating in the acquisitions that further diversified the Company and identifying cost synergy opportunities that contributed to the creation of shareholder value. As a result of Ms. McHugh's significant contributions to the business, and the competitive benchmarks for similar positions, her base salary was increased to \$590,000, reflecting both merit and market-based adjustments, effective March 1, 2012. Further, Ms. McHugh was awarded an annual performance bonus equal to 141.6% of her target and an equity award equal to 120% of her target.

Ivan P. Gergel, M.D.

Executive Vice President, Research & Development & Chief Scientific Officer

Dr. Gergel leads the Company's research and development function, involving the continued advancement of the Company's portfolio through targeted selection of key investment opportunities while accelerating the development of strategic assets. Dr. Gergel has led the expansion of the Company's research & development pipeline, continuing

the advancement of discovery programs in oncology, urology and pain, while developing and progressing a significant number of urology medical device programs. The recent approvals of FORTESTA[®] Gel and the new crush-resistant formulation of Opana[®] ER were important milestones for our urology and pain franchises and will contribute to our revenue growth this year. As a result of Dr. Gergel's leadership role in advancing the Company's diversified product pipeline and positioning the business for long-term success, he received a merit increase of 3.0% effective March 1, 2012. Dr. Gergel was also awarded an annual performance bonus equal to 118% of his target and an equity award equal to 110% of his target.

Caroline B. Manogue

Executive Vice President, Chief Legal Officer & Secretary

Ms. Manogue serves as the Company's Chief Legal Officer and has responsibility for the offices of the corporate secretary and government affairs. Ms. Manogue has broad-based technical and business acumen, providing advice on significant legal and business matters to the Board, President and Chief Executive Officer and other key Company executives. Ms. Manogue has exhibited excellent organizational and functional leadership in effectively managing significant legal matters, and has contributed greatly to the Company's business development strategy. Ms. Manogue demonstrated outstanding leadership and dedication that significantly impacted the Company's acquisitions of AMS, Intuitive Medical Software LLC and meridianEMR, Inc., playing a key role in critical aspects of the business development and financing processes, including diligence, contract development, transaction negotiation and integration activities. Based on Ms. Manogue's broad-based contributions to the Company's overall results, she received a merit increase of 4.1%, effective March 1, 2012. Further, Ms. Manogue was awarded an annual performance bonus equal to 147.5% of her target and an equity award equal to 125% of her target.

Additional Compensation Components

The Company's current practice is to limit use of perquisites. In 2011, other than as described below, the only perquisites provided to the NEOs were financial planning services, use of a company car or car services and term life insurance. In connection with Mr. Levin's joining the Company as our Executive Vice President, Chief Financial Officer in June 2009, the Company agreed to provide him with an automobile or, in

lieu of receiving use of an automobile, the Company agreed to reimburse Mr. Levin for reasonable costs for car services up to \$22,000 per calendar year.

Retirement and Post-Termination Benefits

Retirement Benefits. The Company currently offers two executive retirement programs: the 401(k) Restoration Plan and the Executive Deferred Compensation Plan, each of which is described below. Both plans were effective January 1, 2008, and were amended and restated early in 2012).

401(k) Restoration Plan. The purpose of the 401(k) Restoration Plan (Parity Plan) is to provide eligible employees with the opportunity to defer a portion of their compensation on a tax-favored basis in parity with the tax benefit provided under the qualified 401(k) plan. The 401(k) Parity Plan allows eligible employees whose compensation exceeds the Internal Revenue Code Section 401(a)(17) amount (or other criteria set by the Compensation Committee), including NEOs, to defer eligible pay and receive company matching contributions after such individual's compensation has exceeded the earnings maximum in the Company's existing qualified 401(k) plan. The amount in any individual's 401(k) Parity Plan account will be paid to such individual at termination of employment. Actual 401(k) Parity Plan participation will begin when an executive's total cash compensation exceeds the Internal Revenue Code earnings limit for the qualified 401(k) (\$250,000 for 2012). Individuals who elect to defer their eligible pay under the 401(k) Parity Plan will defer federal and state (to the extent allowed by state law) taxes until the account is paid to the individual.

Table of Contents

Executive Deferred Compensation Plan. The Executive Deferred Compensation Plan permits executives to elect to defer up to 100% of the portion of the following year's LTI compensation that is in the form of RSUs. The RSUs will vest while deferred. The 2012 grant of RSUs to executives will vest ratably over four years.

Deferral of the RSUs defers federal and state (as allowed under state laws) taxes on the compensation when the RSUs vest. The compensation is deferred until the deferred RSUs are settled in stock. The RSUs may be deferred to a specified payment date on which the elected disbursement(s) under the participant's account will commence. The value of the compensation an executive receives upon the stock delivery is based on the value of the Company's common stock on the date the deferral is delivered to the executive, and the executive will be responsible for the federal and state taxes at that time.

The Executive Deferred Compensation Plan also allows an executive to defer up to 50% of his or her annual cash IC award. When an executive makes his or her irrevocable election to defer cash IC, he or she also elects a specific payment date in which the elected disbursement(s) under the participant's account will commence.

Employment and Change in Control Agreements; Severance Agreements. The Company generally enters into a written employment agreement with each of its NEOs. The purpose of these agreements is to aid recruitment and retention and to reinforce an ongoing commitment to shareholder value creation.

On March 12, 2008, the Company announced that David P. Holveck had been named the Company's President and Chief Executive Officer, with effect from April 1, 2008. The Company entered into an employment agreement with Mr. Holveck as of April 1, 2008, which was amended and restated on October 27, 2011. On April 11, 2008, the Company announced that Ivan P. Gergel, M.D. had been named the Company's Executive Vice President, Research and Development & Chief Scientific Officer, effective April 29, 2008. The Company entered into an employment agreement with Dr. Gergel as of April 11, 2008, which was amended and restated on October 27, 2011. On May 7, 2009, the Company announced that Alan G. Levin had been named the Company's Executive Vice President, Chief Financial Officer, effective June 1, 2009. The Company entered into an employment agreement with Mr. Levin as of May 7, 2009. On March 12, 2010, the Company announced that Julie H. McHugh had been named the Company's Chief Operating Officer effective March 12, 2010. The Company entered into an employment agreement with Ms. McHugh as of March 12, 2010. The Company has affirmatively determined not to enter into any future employment agreements that include excise tax gross-ups with respect to payments contingent upon a change in control, as demonstrated by the employment agreements entered into with Mr. Holveck, Mr. Levin, Ms. McHugh and Dr. Gergel. Ms. Manogue's employment agreement has a rolling twenty-four month employment period commencing each day after January 1, 2008 and ending on the twenty-four month anniversary of such day (the Employment Period), unless either the Company or Ms. Manogue elects to terminate her employment agreement. Mr. Holveck's, Dr. Gergel's and Mr. Levin's employment agreements each has an initial term of three years. Mr. Holveck and Dr. Gergel's employment agreements were amended further to exclude automatic renewal provisions. Mr. Levin's employment agreement renews automatically for a successive one-year period unless 120 days' notice of non-renewal is given by either party or unless either the Company or Mr. Levin elects to terminate his employment agreement. Ms. McHugh's employment agreement has an initial term of three years and renews automatically for two additional one-year periods unless 120 days' notice of non-renewal is given by either party. We refer to the employment period for each named executive officer as the Employment Period. Each Employment Agreement sets forth the annual salary of the respective named executive officer, which is, in each case, subject to annual reviews, at the discretion of the Compensation Committee.

Each named executive officer will be paid cash IC in an amount equal to a set percentage of his or her annual salary for each year (or such lesser or greater amount (not to exceed two hundred twenty-five percent of the target bonus amount) for such year) amount as is recommended and approved by the Compensation Committee) if the Company achieves certain performance targets set by the Compensation Committee for such year.

Each named executive officer is eligible to earn as additional compensation for the services to be rendered pursuant to his or her employment agreement, if applicable, equity-based LTI in an amount approved by the Compensation Committee.

If any of the named executive officers terminates his or her employment agreement for Good Reason or if the Company terminates him or her Without Cause, the Company will (i) pay a lump sum equal to two times his or her then current salary and target IC for the year in which the termination is effective and (ii) continue to provide such named executive officer with medical and life insurance benefits for twenty-four (24) months. If Ms. Manogue is terminated other than for Cause or quits for Good Reason within twenty-four (24) months of a Change In Control, then she will be entitled to receive (x) a lump sum payment equal to two times the sum of (1) her then current salary plus (2) the higher of (a) her target IC for the year during which the termination is effective or (b) her IC for the year immediately preceding the year in which the termination is effective, plus (y) medical and life insurance benefits for a period equal to twenty-four (24) months after the date on which the termination is effective. If Mr. Levin or Ms. McHugh is terminated other than for Cause or quits for Good Reason within twenty-four (24) months of a Change In Control, then such named executive officer will be entitled to receive (x) a lump sum payment equal to two times the sum of (1) such named executive officer's then current salary plus (2) such named executive officer's target bonus, plus (y) medical and life

insurance benefits for a period equal to

Table of Contents

twenty-four (24) months after the date on which the termination is effective. Each named executive officer's employment agreement contains a non-compete provision.

Tax Deductibility of Compensation

Section 162(m) of the Internal Revenue Code precludes a public corporation from taking a tax deduction for certain compensation in excess of \$1 million in any one year paid to its Chief Executive Officer or any of its three other highest-paid executive officers (not including the Company's Chief Financial Officer), unless certain specific and detailed criteria are satisfied. However, certain qualifying performance-based compensation (i.e., compensation paid under a plan administered by a committee of outside directors, based on achieving objective performance goals, the material terms of which were approved by shareholders, such as our 2010 Stock Incentive Plan) is not subject to the \$1 million deduction limit. A portion of the compensation established by the Compensation Committee for 2011 for the President and Chief Executive Officer exceeded the \$1 million deduction limit established in Section 162(m) of the Internal Revenue Code and is therefore not deductible. Compensation established by the Compensation Committee for 2011 for the three other highest-paid executive officers (not including the Company's Executive Vice President & Chief Financial Officer) was also designed to comply with the requirements of Section 162(m). While the Compensation Committee considers the applicable rules regarding deductibility when making awards, it reserves the right to make nondeductible payments when it deems appropriate.

Company Policy on Parachute Payments

On May 5, 2009, the Company's Board of Directors adopted a policy that provides that the Company will not enter into any future employment agreements that include excise tax gross-ups with respect to payments contingent upon a change in control. Accordingly, the employment agreement of each of Mr. Holveck, Mr. Levin, Ms. McHugh and Dr. Gergel does not include excise tax gross-ups with respect to payments contingent upon a change in control. Ms. Manogue's employment agreement currently provides that, if any of the payments or benefits received or to be received by the executive (including any payment or benefits received in connection with a change of control or the executive's termination of employment) will be subject to the excise tax under Section 4999 of the Internal Revenue Code for excess parachute payments, then the Company will pay to the executive an additional amount (an excise tax gross-up) such that the net amount retained by the executive, after deduction of any excise tax on and any federal, state and local income and employment taxes and after taking into account the phase out of itemized deductions and personal exemptions attributable to this payment, shall be equal to the total payments the executive would have otherwise received. An excess parachute payment is generally a change in control payment in excess of one times the average of the officer's taxable W-2 income for the five years prior to the change in control (base amount), and generally only results if the change in control payment exceeds 2.99 times the base amount. Excess parachute payments, including any excise tax gross-up payments, are non-deductible to the Company under Section 280G of the Internal Revenue Code.

Recovery of Compensation

In 2009, the Compensation Committee adopted a compensation recovery policy relating to repayment of cash incentive awards by an executive in the event of a restatement of the Company's financial results.

Specifically, if the Company issues a restatement of its reported financial results, or if it is determined that there was executive misconduct in a prior period that impacted the financial results for that period, the Compensation Committee will determine whether the restatement was material, and if so, to what extent covered payments should be returned to the Company to the extent that such payments were overstated as a result of the change in financial condition. Restatements of financial results that are the direct result of changes in accounting standards will not result in recovery of covered payments.

Covered payments are those payments that are eligible to be recovered by the Company and include cash incentives paid to the NEOs for performance during the restated fiscal year(s). In addition, the Compensation Committee reserves the discretion to recover covered payments from other Company senior management employees, including all vice presidents and above, if the Compensation Committee deems it appropriate.

Table of Contents**Compensation of Executive Officers and Directors****Summary Compensation Table**

The following table sets forth the cash and non-cash compensation paid to or earned by our President and Chief Executive Officer, Executive Vice President & Chief Financial Officer and the other three most highly compensated executive officers of the Company (collectively, the NEOs) for the years ending December 31, 2011, 2010 and 2009. For a complete understanding of the table, please read the footnotes and narrative disclosures that follow the table.

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)(1)	Option Awards (\$)(1)	Non-Equity Incentive Plan Compensation (\$)(2)	All Other Compensation (\$)(3)	Total (\$)
David P. Holveck <i>President and Chief Executive Officer</i>	2011	\$ 1,063,667	\$ -	\$ 3,528,008	\$ 1,760,933	\$ 1,869,120	\$ 155,433	\$ 8,377,161
	2010	\$ 875,000	\$ -	\$ 2,374,507	\$ 1,222,133	\$ 1,984,500	\$ 146,318	\$ 6,602,458
	2009	\$ 833,333	\$ -	\$ 979,998	\$ 2,995,240	\$ 739,200	\$ 136,596	\$ 5,684,367
Alan G. Levin (4) <i>Executive Vice President & Chief Financial Officer</i>	2011	\$ 638,833	\$ -	\$ 1,112,370	\$ 555,231	\$ 563,364	\$ 21,103	\$ 2,890,901
	2010	\$ 615,000	\$ -	\$ 852,891	\$ 438,969	\$ 556,756	\$ 23,837	\$ 2,487,453
	2009	\$ 350,000	\$ 225,000	\$ 718,185	\$ 691,692	\$ 363,000	\$ 12,435	\$ 2,360,312
Julie H. McHugh (5) <i>Chief Operating Officer</i>	2011	\$ 555,833	\$ -	\$ 1,070,030	\$ 534,075	\$ 475,776	\$ 92,438	\$ 2,728,152
	2010	\$ 425,599	\$ -	\$ 334,364	\$ 1,000,084	\$ 465,129	\$ 50,984	\$ 2,276,160
Ivan P. Gergel, M.D. <i>Executive Vice President,</i>	2011	\$ 632,833	\$ -	\$ 904,956	\$ 451,683	\$ 412,764	\$ 113,314	\$ 2,515,550
	2010	\$ 613,546	\$ -	\$ 886,129	\$ 456,077	\$ 763,538	\$ 136,923	\$ 2,856,213
<i>Research & Development</i>	2009	\$ 592,729	\$ -	\$ 313,379	\$ 944,996	\$ 360,746	\$ 1,018,658	\$ 3,230,508
<i>& Chief Scientific Officer</i>								
Caroline B. Manogue <i>Executive Vice President,</i>	2011	\$ 526,667	\$ -	\$ 797,306	\$ 397,980	\$ 438,075	\$ 87,315	\$ 2,247,343
	2010	\$ 454,833	\$ -	\$ 519,708	\$ 267,498	\$ 414,414	\$ 78,857	\$ 1,735,310
<i>Chief Legal Officer & Secretary</i>	2009	\$ 423,404	\$ -	\$ 215,204	\$ 648,965	\$ 235,950	\$ 80,560	\$ 1,604,083

- The amounts shown in this column represent the grant date fair value for each executive's awards under ASC 718. The grant date fair value of the portion of our PSUs which are earned based on the Company's net sales performance was determined using the closing price of the Company's stock on the grant date. The grant date fair value of the portion of our PSUs which are earned based on the Company's TSR performance was determined using a Monte-Carlo variant valuation model, which considers a variety of potential future stock prices for Endo as well as our peer companies in a selected market index. See further discussion of the provisions of our PSUs above in the Performance Shares Units section above. See notes 13, 13 and 12 to our audited financial statements included in our 2011, 2010 and 2009 Annual Reports on Form 10-K, respectively, for the assumptions we used in valuing and expensing these awards in accordance with ASC 718.
- The amounts shown in this column represent cash amounts earned pursuant to the Company's IC program with respect to 2011, 2010 and 2009 performance, respectively. These amounts were awarded by the Committee on February 22, 2012, February 23, 2011 and February 19, 2010, respectively.
- The amounts shown in this column for 2011 include the items summarized in the table below:

Name and Principal	Perquisites & Other Personal	Registrant Contributions	Life Insurance	Tax Reimbursements (d)	Other	Total
--------------------	------------------------------	--------------------------	----------------	------------------------	-------	-------

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

Position	Benefits (a)		to Defined Contribution Plans (b)		Premiums (c)							
David P. Holveck	\$	10,000	\$	123,355	\$	15,408	\$	6,670	\$	-	\$	155,433
Alan G. Levin	\$	3,698	\$	14,700	\$	2,705	\$	-	\$	-	\$	21,103
Julie H. McHugh	\$	29,920	\$	61,258	\$	1,260	\$	-	\$	-	\$	92,438
Ivan P. Gergel, M.D.	\$	18,995	\$	83,782	\$	3,122	\$	7,415	\$	-	\$	113,314
Caroline B. Manogue	\$	20,652	\$	56,465	\$	1,100	\$	9,098	\$	-	\$	87,315

- a Mr. Holveck received \$10,000 for financial planning services. Mr. Levin received \$3,698 for travel allowance. Ms. McHugh received \$21,600 for car allowance and related costs and \$8,320 for financial planning services. Dr. Gergel received \$12,122 for car allowance and related costs, \$4,572 for financial planning services and \$2,301 for relocation expenses. Ms. Manogue received \$9,553 for car allowance and related costs and \$11,099 for financial planning services.
- b Represents the employers' matching contribution to the Company's Savings and Investment (401(k)) Plan and the Parity Plan.
- c Represents annual premiums paid by the Company for executive term life insurance policies.

Table of Contents

- d The amounts shown in this column represent the reimbursement of taxes associated with perquisites and other benefits.
- 4 Mr. Levin joined the Company as its Executive Vice President, Chief Financial Officer on June 1, 2009. Accordingly, his annualized 2009 base salary of \$600,000 was pro-rated. His 2009 IC and LTI compensation were not pro-rated. As described in more detail below under the section titled Employment and Change in Control Agreements; Severance Agreements, in connection with his commencement of employment with the Company on June 1, 2009, Mr. Levin, our Executive Vice President & Chief Financial Officer, was granted on such date (a) restricted stock units of 43,500 and (b) stock options of 80,000. Due to an administrative error, the Company cancelled a portion of the non-qualified stock options and replaced the cancelled awards with a new grant of incentive stock options on July 28, 2009. The total number of options granted in 2009 exceeded the 80,000 options per his employment agreement due to the increased exercise price on July 28, 2009. The cancellation and re-granting of awards was intended for Mr. Levin to be in the same economic position as he would have been under the original terms of his employment agreement.
- 5 Ms. McHugh joined the Company as its Chief Operating Officer on March 15, 2010. Accordingly, her annualized 2010 base salary of \$535,000 was pro-rated. Her 2010 IC and LTI compensation were not pro-rated. As described in more detail in her employment agreement under the section titled Initial Equity Grants, in connection with her commencement of employment with the Company on March 15, 2010, Ms. McHugh, our Chief Operating Officer, was granted on such date (a) restricted stock units equal in value to \$334,364 and (b) stock options equal in value to \$1,000,084.

The employment agreements, short-term and long-term incentive compensation program and awards, explanation of amount of salary and bonus in proportion to total compensation, and other elements of the Summary Compensation Table are discussed at length in the COMPENSATION DISCUSSION AND ANALYSIS above.

2011 Grants of Plan-Based Awards

The following table summarizes grants of plan-based awards made to the NEOs during the year ended December 31, 2011.

Current NEOs	Grant Date (1)	Threshold Estimated Future Payouts Under Non- Estimated Future Payouts Under Equity Incentive Plan						All Other Stock Awards (number of shares of stocks or units)	All Other Option Awards (number of securities underlying options)	Exercise or Base Price of Option Awards (\$/Sh)	Grant Date Fair Value of Stock & Option Awards (5)
		Equity Incentive Plan Awards (2)		Awards (3)		Target Maximum (\$)(6) (#)	Maximum (\$)(7)				
		Grant Date (1)	Threshold (\$)	Maximum (\$)(6)	Target Maximum (\$)(7)						
			Target (\$)				(#)(4)	(#)(4)	(\$/Sh)	Awards (5)	
David P. Holveck	23 Feb 11	\$ -	\$ 1,320,000	\$ 2,970,000	-	-	-	161,983	\$ 33.98	\$ 1,760,933	
	23 Feb 11	\$ -	\$ -	\$ -	-	-	51,913	-	\$ -	\$ 1,764,004	
	23 Feb 11	\$ -	\$ -	\$ -	-	51,913	103,826	-	\$ -	\$ 1,764,004	
Alan G. Levin	23 Feb 11	\$ -	\$ 353,650	\$ 795,713	-	-	-	51,074	\$ 33.98	\$ 555,231	
	23 Feb 11	\$ -	\$ -	\$ -	-	-	16,368	-	\$ -	\$ 556,185	
	23 Feb 11	\$ -	\$ -	\$ -	-	16,368	32,736	-	\$ -	\$ 556,185	
Julie H. McHugh	23 Feb 11	\$ -	\$ 336,000	\$ 756,000	-	-	-	49,128	\$ 33.98	\$ 534,075	
	23 Feb 11	\$ -	\$ -	\$ -	-	-	15,745	-	\$ -	\$ 535,015	
	23 Feb 11	\$ -	\$ -	\$ -	-	15,745	31,490	-	\$ -	\$ 535,015	
Ivan P. Gergel, M.D.	23 Feb 11	\$ -	\$ 349,800	\$ 787,050	-	-	-	41,549	\$ 33.98	\$ 451,683	
	23 Feb 11	\$ -	\$ -	\$ -	-	-	13,316	-	\$ -	\$ 452,478	
	23 Feb 11	\$ -	\$ -	\$ -	-	13,316	26,632	-	\$ -	\$ 452,478	
Caroline B. Manogue	23 Feb 11	\$ -	\$ 297,000	\$ 668,250	-	-	-	36,609	\$ 33.98	\$ 397,980	
	23 Feb 11	\$ -	\$ -	\$ -	-	-	11,732	-	\$ -	\$ 398,653	
	23 Feb 11	\$ -	\$ -	\$ -	-	11,732	23,464	-	\$ -	\$ 398,653	

1 The grant date of all awards is the date of the Board of Directors action in which such award is approved.
 2 The amounts shown in these columns represent the range of IC program payouts targeted for 2011 performance as described in the section titled Performance-Based Annual Cash Incentive Compensation (IC) in the COMPENSATION DISCUSSION AND ANALYSIS above.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

There is no threshold for this award. The bonus payment for 2011 performance has been made according to the metrics described and is shown in the Summary Compensation Table in the column titled "Non-Equity Incentive Plan Compensation."

- 3 The amounts shown in these columns represent the range of shares that may be released at the end of the three-year performance period applicable to our PSUs assuming achievement of the relevant performance objectives, as described in the section titled "Equity-Based Long-term Incentive (LTI) Compensation" in the "COMPENSATION DISCUSSION AND ANALYSIS" above. There is no threshold for this award. The PSU awards granted in 2011 were made according to the metrics described and are included in the Summary Compensation Table in the column titled "Stock Awards."

Table of Contents

- 4 These options and restricted stock units were granted in 2011 based on the Company's 2010 LTI compensation payout. The 2011 equity incentive payout was made in February 2012 and is shown in more detail below:

2011 Long-Term Equity Incentive Compensation:			2011 Long-Term Equity Incentive Compensation:		
Number of Securities Underlying Stock Options		Exercise or Base Price of	Restricted Stock Units (RSU) and Performance	Grant Date Fair Value of RSU, PSU & Option Awards	
Name	(#)	Option Awards (\$/Sh)(a)	Share Units (PSU) (#)(b)	(c)	
David P. Holveck	173,940	\$ 34.70	105,668	\$	5,500,000
Alan G. Levin	54,905	\$ 34.70	33,354	\$	1,736,100
Julie H. McHugh	53,131	\$ 34.70	32,276	\$	1,680,000
Ivan P. Gergel, M.D.	44,250	\$ 34.70	26,882	\$	1,399,200
Caroline B. Manogue	42,694	\$ 34.70	25,936	\$	1,350,000

- a The exercise price is equal to the closing price on the date of grant, which was February 22, 2012.
 - b The amounts shown in this column represent approximately 50% RSUs and 50% PSUs on the date of grant.
 - c The amounts shown in this column include the fair value under ASC 718 of the 2011 option awards on the date of grant determined using the Black-Scholes or Monte-Carlo variant valuation model, as appropriate. Additionally, amounts reflect the grant-date fair value of the PSUs which include both a performance and market-based variable as defined within ASC 718. Although the fair value of executive award grants listed above has been determined in accordance with the applicable accounting standards, values may not be indicative of the fair value observed in a willing buyer / willing seller market transaction.
- 5 The amounts shown in this column represent the fair value under ASC 718 of awards granted in 2011 valued on the date of grant (even if not yet vested) determined using the Black-Scholes or Monte-Carlo variant valuation model, as appropriate.
- 6 For the current NEOs, the amounts shown in this column represent the maximum IC payout as approved by the Board.
- 7 For the current NEOs, the amounts shown in this column represent the maximum number of shares related to our PSUs that could ultimately be released at the end of the three-year performance period.

See COMPENSATION DISCUSSION AND ANALYSIS above regarding the material terms, determining amounts payable, vesting schedule and other material conditions of these grants.

Outstanding Equity Awards at December 31, 2011

The following table summarizes the number of securities underlying outstanding plan awards for the NEOs during the year ended December 31, 2011:

Name	Option Awards				Stock Awards			
	Number of Securities Underlying Unexercised Options Exercisable	Number of Securities Underlying Unexercised Options	Option Exercise Price (\$)	Option Expiration Date	Number of Shares of Stock That Have Not Vested (#)	Market Value of Stock That Have Not Vested (\$)(7)	Equity Incentive Plan Awards: Number of Unearned Shares, Units	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

	(#)	(#)	(#)	(#)	(#)	(#)	(#)	(#)	(#)	(#)	(#)
		Securities	Underlying	Unexercised	Unearned	Options	or Other	Rights That	Have Not	Other Rights	That
								Have Not	Vested	That	Have Not
								Vested (#)	(#)		(#)
David P. Holveck	-	161,983	- \$ 33.98	23-Feb-2021	-	\$ -	-	\$ -	-	\$ -	-
	42,184	126,549	- \$ 20.61	19-Feb-2020	-	\$ -	-	\$ -	-	\$ -	-
	191,407	191,406	- \$ 19.93	26-Feb-2019	-	\$ -	-	\$ -	-	\$ -	-
	141,474	47,158	- \$ 24.41	01-Apr-2018	-	\$ -	-	\$ -	-	\$ -	-
	-	-	- \$ -	-	166,924(2)	\$ 5,763,886	-	\$ -	-	\$ -	-
	-	-	- \$ -	-	-	-	-	\$ -	111,350(2)	\$ 3,844,916	-
Alan G. Levin	-	51,074	- \$ 33.98	23-Feb-2021	-	\$ -	-	\$ -	-	\$ -	-
	15,152	45,454	- \$ 20.61	19-Feb-2020	-	\$ -	-	\$ -	-	\$ -	-
	4,978	9,954	- \$ 20.09	28-Jul-2019	-	\$ -	-	\$ -	-	\$ -	-
	16,626	33,251	- \$ 16.51	01-Jun-2019	-	\$ -	-	\$ -	-	\$ -	-
	-	-	- \$ -	-	59,467(3)	\$ 2,053,396	-	\$ -	-	\$ -	-
	-	-	- \$ -	-	-	-	-	\$ -	37,717(3)	\$ 1,302,368	-
Julie H. McHugh	-	49,128	- \$ 33.98	23-Feb-2021	-	\$ -	-	\$ -	-	\$ -	-
	30,070	90,209	- \$ 23.81	15-Mar-2020	-	\$ -	-	\$ -	-	\$ -	-
	-	-	- \$ -	-	26,277(4)	\$ 907,345	-	\$ -	-	\$ -	-
	-	-	- \$ -	-	-	-	-	\$ -	15,745(4)	\$ 543,675	-

Table of Contents

Name	Option Awards				Stock Awards					
	Number of Securities Underlying Unexercised Options Exercisable	Number of Securities Underlying Unexercised Options Not Exercisable	Number of Securities Underlying Exercised Options	Option Exercise Price	Option Expiration Date	Number of Shares of Stock That Have Not Vested	Market Value of Shares of Stock That Have Not Vested	Shares, Units or Other Rights That Have Not Vested	Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested	Value of Unearned Shares, Units or Other Rights That Have Not Vested
Ivan P. Gergel, M.D.	-	41,549	-	\$ 33.98	23-Feb-2021	-	\$ -	-	\$ -	-
	-	47,226	-	\$ 20.61	19-Feb-2020	-	\$ -	-	\$ -	-
	-	61,206	-	\$ 19.93	26-Feb-2019	-	\$ -	-	\$ -	-
	-	12,500	-	\$ 25.02	29-Apr-2018	-	\$ -	-	\$ -	-
	-	-	-	\$ -	-	51,221(5)	\$ 1,768,661	-	\$ -	-
	-	-	-	\$ -	-	-	-	35,497(5)	\$ 1,225,711	-
Caroline B. Manogue	-	36,609	-	\$ 33.98	23-Feb-2021	-	\$ -	-	\$ -	-
	9,233	27,699	-	\$ 20.61	19-Feb-2020	-	\$ -	-	\$ -	-
	42,033	42,032	-	\$ 19.93	26-Feb-2019	-	\$ -	-	\$ -	-
	30,542	10,180	-	\$ 25.19	21-Feb-2018	-	\$ -	-	\$ -	-
	50,000	-	-	\$ 24.87	25-Jan-2018	-	\$ -	-	\$ -	-
	42,279	-	-	\$ 30.55	21-Feb-2017	-	\$ -	-	\$ -	-
	130,000	-	-	\$ 28.61	14-Feb-2016	-	\$ -	-	\$ -	-
	35,000	-	-	\$ 15.24	05-Aug-2013	-	\$ -	-	\$ -	-
	-	-	-	\$ -	-	38,331(6)	\$ 1,323,569	-	\$ -	-
	-	-	-	\$ -	-	-	-	24,741(6)	\$ 854,307	-

(1) The vesting dates of each option grant are listed in the table below by expiration date:

Expiration Date	Vesting Date	Expiration Date	Vesting Date
23-Feb-2021	25% on February 23, 2012	1-Apr-2018	25% on April 1, 2009
	25% on February 23, 2013		25% on April 1, 2010
	25% on February 23, 2014		25% on April 1, 2011
	25% on February 23, 2015		25% on April 1, 2012
15-Mar-2020	25% on March 15, 2011	21-Feb-2018	25% on February 21, 2009
	25% on March 15, 2012		25% on February 21, 2010
	25% on March 15, 2013		25% on February 21, 2011
	25% on March 15, 2014		25% on February 21, 2012
19-Feb-2020	25% on February 19, 2011	25-Jan-2018	50% on January 25, 2009
	25% on February 19, 2012		50% on January 25, 2010
	25% on February 19, 2013		

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

	25% on February 19, 2014		
28-Jul-2019	25% on July 28, 2010	21-Feb-2017	25% on February 21, 2008
	25% on July 28, 2011		25% on February 21, 2009
	25% on July 28, 2012		25% on February 21, 2010
	25% on July 28, 2013		25% on February 21, 2011
1-Jun-2019	25% on June 1, 2010	14-Feb-2016	25% on February 14, 2007
	25% on June 1, 2011		25% on February 14, 2008
	25% on June 1, 2012		25% on February 14, 2009
	25% on June 1, 2013		25% on February 14, 2010
26-Feb-2019	25% on February 26, 2010	5-Aug-2013	25% on August 5, 2004
	25% on February 26, 2011		25% on August 5, 2005
	25% on February 26, 2012		25% on August 5, 2006
	25% on February 26, 2013		25% on August 5, 2007
29-Apr-2018	25% on April 29, 2009		
	25% on April 29, 2010		
	25% on April 29, 2011		
	25% on April 29, 2012		

Table of Contents

- (2) These amounts are comprised of 6,402 RSUs granted on April 1, 2008 (which vest on the fourth anniversary of the date of grant), 49,172 RSUs granted on February 26, 2009 (which vest on the fourth anniversary of the date of grant), 59,437 RSUs granted on February 19, 2010 (which vest on the fourth anniversary of the date of grant), 59,437 PSUs granted on February 19, 2010 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2012, the first business day following the end of their performance period), 51,913 RSUs granted on February 23, 2011 (which vest ratably over a four-year period in 25% increments on each of the first, second, third, and fourth anniversaries of the date of grant) and 51,913 PSUs granted on February 23, 2011 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2013, the first business day following the end of their performance period).
- (3) These amounts are comprised of 21,750 RSUs granted on June 1, 2009 (which will vest ratably over their remaining term in equal increments on each of the third and fourth anniversaries of the date of grant), 21,349 RSUs granted on February 19, 2010 (which vest on the fourth anniversary of the date of grant), and 21,349 PSUs granted on February 19, 2010 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2012, the first business day following the end of their performance period), 16,368 RSUs granted on February 23, 2011 (which vest ratably over a four-year period in 25% increments on each of the first, second, third, and fourth anniversaries of the date of grant) and 16,368 PSUs granted on February 23, 2011 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2013, the first business day following the end of their performance period).
- (4) This amount is comprised of 10,532 RSUs granted on March 15, 2010 (which will vest ratably over their remaining term on each of the second, third, and fourth anniversaries of the date of grant), 15,745 RSUs granted on February 23, 2011 (which vest ratably over a four-year period in 25% increments on each of the first, second, third, and fourth anniversaries of the date of grant) and 15,745 PSUs granted on February 23, 2011 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2013, the first business day following the end of their performance period).
- (5) These amounts are comprised of 15,724 RSUs granted on February 26, 2009 (which vest on the fourth anniversary of the date of grant), 22,181 RSUs granted on February 19, 2010 (which vest on the fourth anniversary of the date of grant), and 22,181 PSUs granted on February 19, 2010 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2012, the first business day following the end of their performance period), 13,316 RSUs granted on February 23, 2011 (which vest ratably over a four-year period in 25% increments on each of the first, second, third, and fourth anniversaries of the date of grant) and 13,316 PSUs granted on February 23, 2011 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2013, the first business day following the end of their performance period).
- (6) These amounts are comprised of 2,792 RSUs granted on February 21, 2008 (which vest on the fourth anniversaries of the date of grant), 10,798 RSUs granted on February 26, 2009 (which vest on the fourth anniversary of the date of grant), 13,009 RSUs granted on February 19, 2010 (which vest on the fourth anniversary of the date of grant), 13,009 PSUs granted on February 19, 2010 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2012, the first business day following the end of their performance period), 11,732 RSUs granted on February 23, 2011 (which vest ratably over a four-year period in 25% increments on each of the first, second, third, and fourth anniversaries of the date of grant) and 11,732 PSUs granted on February 23, 2011 (which, upon the achievement of certain financial metrics discussed above, become exercisable on December 31, 2013, the first business day following the end of their performance period).
- (7) Value calculated by multiplying the number of unvested units by the closing price of \$34.53 per share on December 31, 2011.
- (8) Value calculated by multiplying the number of unvested units by the closing price of \$34.53 per share on December 31, 2011. The values shown in this column are based on the number of units that would be earned at target performance. These amounts could range from zero to two times the amounts listed in this column depending on performance in relation to the terms of the PSUs, which are discussed in detail above the section titled *Equity-Based Long-term Incentive (LTI) Compensation* in the *COMPENSATION DISCUSSION AND ANALYSIS*.

Table of Contents**Option Exercises and Stock Vested in 2011**

The following table summarizes the stock option exercises by the NEOs during the year ended December 31, 2011.

Name	Number of Shares Acquired on Exercise (#)	Option Awards		Stock Awards	
		Value Realized on Exercise (\$)(1)	Number of Shares Vesting (#)	Value Realized on Vesting (\$)(2)	
David P. Holveck	-	\$ -	-	\$ -	-
Alan G. Levin	-	\$ -	10,875	\$ -	451,313
Julie H. McHugh	-	\$ -	3,511	\$ -	120,989
Ivan P. Gergel, M.D.	58,845	\$ 868,708	-	\$ -	-
Caroline B. Manogue	55,588	\$ 1,371,624	-	\$ -	-

- (1) Amounts in this column were calculated by determining the difference between the market price of the underlying securities at exercise and the exercise price of the options and multiplying this amount by the number of options exercised.
- (2) Amounts in this column were calculated by determining the market price of the underlying securities on the vesting date and multiplying this amount by the number of awards vested.

2011 Non-Qualified Deferred Compensation Table

The following table summarizes deferral activity during 2011 and account balances in our non-qualified savings and deferral plans for our NEOs. These plans include the Parity Plan and Executive Deferred Compensation Plan, and are available to employees who satisfy certain eligibility requirements, including the NEOs. The Parity and Executive Deferred Compensation Plans are non-qualified under the Internal Revenue Code and do not provide for guaranteed returns of Plan contributions. See COMPENSATION DISCUSSION AND ANALYSIS above regarding the material terms of the Parity and Executive

Name	Executive Contributions in 2011 (\$)(1)	Registrant Contributions in 2011 (\$)(2)	Aggregate		
			Aggregate Earnings in 2011 (\$)(3)	Withdrawals / Distributions (\$)	Aggregate Balance at December 31, 2011 (\$)(4)
David P. Holveck	\$ 1,897,708	\$ 108,655	\$ (151,484)	\$ -	\$ 2,683,036
Alan G. Levin	\$ -	\$ -	\$ -	\$ -	\$ -
Julie H. McHugh	\$ 46,558	\$ 46,558	\$ (1,261)	\$ -	\$ 105,423
Ivan P. Gergel, M.D.	\$ 69,082	\$ 69,082	\$ (24,135)	\$ -	\$ 385,266
Caroline B. Manogue	\$ 41,765	\$ 41,765	\$ (32,504)	\$ -	\$ 219,588

Deferred Compensation Plans.

- (1) Represents amounts contributed by the NEOs under the non-qualified Parity and Executive Deferred Compensation Plans. These amounts are included in the 2011 Summary Compensation Table in the Salary and Non-Equity Incentive Plan Compensation columns.
- (2) Includes amounts that were contributed by the registrant under the non-qualified Parity Plan and reported as compensation in the 2011 Summary Compensation Table in the All Other Compensation column.
- (3) Represents earnings on the Company's Parity and Executive Deferred Compensation Plans. These amounts are not reported as compensation in the Summary Compensation Table.
- (4) Includes amounts that were reported as compensation in the Summary Compensation Table in 2011 and prior years to the extent that such amounts were contributed by the executive and registrant, but not to the extent that such amounts represent earnings.

Table of Contents**Potential Payments Upon Termination or Change in Control**

The following tables show the potential payments upon termination or change of control to the NEOs, as if such event(s) took place on December 31, 2011. The amounts reflected in this table were determined in accordance using each NEO's employment agreement, individual award agreements and the respective Endo Pharmaceuticals Stock Incentive Plan to which each award relates. The equity award acceleration amounts below were calculated using the closing stock price of our stock on December 31, 2011 of \$34.53.

Name	Cash Separation Payment (1)	Health and Welfare and Life Insurance Benefits (2)	Disability Insurance Benefits (3)	Acceleration of Equity Awards (in the money value at December 31, 2011) (4)	Value of Term Life Insurance (5)	Excise Tax Gross-up (6)
<i>Termination for Cause, Resignation or Retirement</i>						
Mr. Holveck	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Mr. Levin	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Ms. McHugh	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Dr. Gergel	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Ms. Manogue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
<i>Death</i>						
Mr. Holveck	\$ -	\$ -	\$ -	14,731,221	1,000,000	\$ -
Mr. Levin	\$ -	\$ -	\$ -	4,759,493	1,000,000	\$ -
Ms. McHugh	\$ -	21,228	\$ -	2,445,081	\$ -	\$ -
Dr. Gergel	\$ -	21,228	\$ -	4,687,093	1,000,000	\$ -
Ms. Manogue	\$ -	\$ -	\$ -	3,292,330	1,000,000	\$ -
<i>Disability</i>						
Mr. Holveck	\$ -	39,989	1,840,000	698,300	\$ -	\$ -
Mr. Levin	\$ -	\$ -	926,000	\$ -	\$ -	\$ -
Ms. McHugh	\$ -	36,463	760,000	\$ -	\$ -	\$ -
Dr. Gergel	\$ -	39,066	912,000	\$ -	\$ -	\$ -
Ms. Manogue	\$ -	\$ -	720,000	\$ -	\$ -	\$ -
<i>Change of Control (COC)</i>						
Mr. Holveck	\$ -	\$ -	\$ -	14,731,221	\$ -	\$ -
Mr. Levin	\$ -	\$ -	\$ -	4,759,493	\$ -	\$ -
Ms. McHugh	\$ -	\$ -	\$ -	2,445,081	\$ -	\$ -
Dr. Gergel	\$ -	\$ -	\$ -	4,687,093	\$ -	\$ -
Ms. Manogue	\$ -	\$ -	\$ -	3,292,330	\$ -	\$ -
<i>Termination Without Cause (TWOC) or Quit for Good Reason (QFGR)</i>						
Mr. Holveck	4,840,000	39,989	\$ -	10,886,305	\$ -	\$ -
Mr. Levin	1,993,300	29,219	\$ -	1,493,946	\$ -	\$ -
Ms. McHugh	1,792,000	36,463	\$ -	887,140	\$ -	\$ -
Dr. Gergel	1,971,600	39,066	\$ -	\$ -	\$ -	\$ -
Ms. Manogue	1,674,000	36,952	\$ -	\$ -	\$ -	\$ -
<i>TWOC or QFGR Within 24 Months After COC</i>						
Mr. Holveck	4,840,000	39,989	\$ -	\$ -	\$ -	\$ -
Mr. Levin	1,993,300	29,219	\$ -	\$ -	\$ -	\$ -
Ms. McHugh	1,792,000	36,463	\$ -	\$ -	\$ -	\$ -
Dr. Gergel	1,971,600	39,066	\$ -	\$ -	\$ -	\$ -
Ms. Manogue	1,908,828	36,952	\$ -	\$ -	\$ -	\$ -

- (1) In the event of a TWOC by the Company or a QFGR by any of the NEOs, the Cash Separation Payment is equal to two times the sum of the NEO's current base salary plus target annual IC, payable in a lump-sum. In the event of TWOC by the Company or a QFGR by any of the NEOs within 24 months after a Change of Control, all NEOs, other than Ms. Manogue, will receive a Cash Separation Payment equal to two times the sum of their current base salary plus target annual IC, payable in a lump-sum. Ms. Manogue, will receive a lump-sum payment equal to two times the sum of her current base salary plus the greater of her (a) current annual IC target or (b) the actual annual IC paid for the preceding year.
- (2) Upon a TWOC by the Company or a QFGR by any of the NEOs (or upon disability for Mr. Holveck, Ms. McHugh and Dr. Gergel only), health and welfare benefits including medical, dental, and vision as well as life insurance benefits will continue to be provided, on a monthly basis, to each NEO for a period of 24 months subsequent to termination. Additionally,

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

in the event of death of Mr. Holveck, Ms. McHugh and Dr. Gergel only, health and welfare benefits

Table of Contents

- including medical, dental, and vision insurance benefits will continue to be provided to their dependents, if any, on a monthly basis, for a period of 24 months.
- (3) Upon disability of any of the NEOs, disability insurance benefits will be paid to the NEO equal to the excess of 24 months' base salary over their respective disability benefits. As of December 31, 2011, the disability insurance benefit for each NEO totaled \$15,000 per month.
- (4) The provisions governing acceleration of equity awards are discussed separately for each scenario below, as follows:
- (a) Upon Death Each of the NEO's unvested stock options and RSUs will accelerate and become immediately vested. PSUs will be deemed to be earned at target levels for each of the NEOs.
- (b) Upon Disability Mr. Holveck's remaining unvested stock options and RSUs from his initial LTI grant will accelerate and become immediately vested.
- (c) Upon a Change of Control Each of the NEO's unvested stock options and RSUs will accelerate and become immediately vested. PSUs are assumed to be issued at target levels for each of the NEOs. If an actual change of control occurred, any performance goals imposed shall be deemed to be fully achieved at the greater of target levels or based upon actual performance through the date immediately prior to the change in control.
- (d) Upon a TWOC by the Company or a QFGR by any of the NEOs All of Mr. Holveck's unvested stock options and RSUs will accelerate and become immediately vested. Additionally, a portion of Mr. Levin's and Ms. McHugh's RSUs and stock options will vest. This portion is determined by the unvested stock options and RSUs that would have vested had the respective NEO remained employed by the Company for two years following termination.
- (5) Each of our NEOs, except Ms. McHugh, is covered by term life insurance policies, the premiums for which are reimbursed by the Company. The premiums for these term life insurance policies are listed above in the "All Other Compensation" table. The amounts included above represent the death benefits that would be received from the insurance provider under these life insurance policies.
- (6) On May 5, 2009, the Company's Board of Directors adopted a policy that provides that the Company does not intend to enter into any future employment agreements that include excise tax gross-ups with respect to payments contingent upon a change in control (as demonstrated by the employment agreements entered into with Mr. Holveck, Mr. Levin, Ms. McHugh and Dr. Gergel which do not include an excise tax gross-up). Under the terms of Ms. Manogue's current employment agreement, should Ms. Manogue become entitled to the Change of Control payments detailed above, the Company will pay to Ms. Manogue an additional lump-sum amount (the Gross-Up Payment) such that the net amount retained by Ms. Manogue, after deduction of any excise tax on excess parachute payments under section 4999 of the Internal Revenue Code (Excise Tax) on the total payments and any federal, state and local income and employment taxes and Excise Tax upon the Gross-Up Payment, and after taking into account the phase out of itemized deductions and personal exemptions attributable to the Gross-Up Payment, shall be equal to the total payments Ms. Manogue would have otherwise received.

2011 Compensation of Non-Employee Directors

The following table provides information concerning the compensation of the Company's non-employee directors for 2011. Directors who are employees of the Company receive no additional compensation for their services as directors or as members of Board committees. For a complete understanding of the table, please read the footnotes and the narrative disclosures that follow the table.

Name	Length of Service	Fees Earned or			Stock		Total
		Paid	in Cash (\$)(1)	Awards (\$)(2)(3)			
Roger H. Kimmel	11 Years	\$	247,500	\$	149,995	\$	397,495
John J. Delucca	6 Years	\$	125,000	\$	149,995	\$	274,995
Nancy J. Hutson, Ph.D.	3 Years	\$	97,000	\$	149,995	\$	246,995
Michael Hyatt	11 Years	\$	104,500	\$	149,995	\$	254,495
William P. Montague	3 Years	\$	105,500	\$	149,995	\$	255,495
David B. Nash, M.D., M.B.A.	1 Year	\$	73,000	\$	149,995	\$	222,995
Joseph C. Scodari	4 Years	\$	100,750	\$	149,995	\$	250,745
William F. Spengler	4 Years	\$	106,500	\$	149,995	\$	256,495

- (1) The amounts in this column include Endo stock paid in lieu of cash compensation to the Company's non-employee directors who elected, pursuant to the Endo Pharmaceuticals Directors Stock Election Plan, to receive all or a portion of their retainer and/or meeting fees in Endo stock. The dollar amounts represent the number of shares granted multiplied by the trading price of Endo's stock at the time of payment. The following table summarizes, for each of the non-employee directors who elected to receive all or a portion of such fees in Endo stock, the amounts of such non-cash compensation:

Table of Contents

Name	Fees Paid in Shares of Endo Common Stock (\$)
William P. Montague	\$ 26,375
Joseph C. Scodari	\$ 100,750
William F. Spengler	\$ 106,500

- (2) The amounts shown in these columns represent the grant date fair value for each director's stock-based awards under ASC 718. See notes 13, 13 and 12 to our audited financial statements included in our 2011, 2010 and 2009 Annual Reports on Form 10-K, respectively, for the assumptions we used in valuing and expensing these awards in accordance with ASC 718. The grant date fair value of each option and stock award granted in 2011, computed in accordance with ASC 718, is as follows:

Name	Grant Date	Fair Value on Grant Date of Restricted Stock
Roger H. Kimmel	March 14, 2011	\$ 149,995
John J. Delucca	March 14, 2011	\$ 149,995
Nancy J. Hutson, Ph.D.	March 14, 2011	\$ 149,995
Michael Hyatt	March 14, 2011	\$ 149,995
William P. Montague	March 14, 2011	\$ 149,995
David B. Nash, M.D., M.B.A.	March 14, 2011	\$ 149,995
Joseph C. Scodari	March 14, 2011	\$ 149,995
William F. Spengler	March 14, 2011	\$ 149,995

- (3) The following table summarizes the number of stock options and restricted stock outstanding and exercisable at December 31, 2011, for each Director in 2011:

Name	Options Exercisable Outstanding at Fiscal Year End	Options Exercisable at Fiscal Year End	Options Exercisable Shares Outstanding at Fiscal Year End	Options Exercisable Shares Vested at Fiscal Year End	Options Exercisable Value at Fiscal Year End (a)
Roger H. Kimmel	49,809	36,856	13,853	10,438	\$ 993,222
John J. Delucca	39,809	26,856	5,677	10,438	\$ 586,205
Nancy J. Hutson, Ph.D.	18,185	7,070	5,677	5,325	\$ 456,884
Michael Hyatt	64,809	51,856	5,677	10,438	\$ 969,405
William P. Montague	18,478	7,216	11,112	5,435	\$ 654,492
David B. Nash, M.D., M.B.A.	-	-	4,260	-	\$ 147,098
Joseph C. Scodari	23,649	11,095	5,677	7,553	\$ 521,790
William F. Spengler	23,649	11,095	11,112	7,553	\$ 709,460

- (a) Based upon the closing price on December 31, 2011 of \$34.53. Includes all outstanding options as of December 31, 2011, for which the exercise price is equal to or less than \$34.53 per share.

Annual Cash Retainer Fees. For 2011, each non-employee director who was not affiliated with the Company (a Non-Affiliated Director) received \$12,500 cash in the first and second quarter of service and \$15,000 in the third and fourth quarter. In addition, any Non-Affiliated Director who serves as the Chair of the Audit Committee, the Compensation Committee or the Transactions Committee receives an additional fee of \$15,000 cash per year, and any Non-Affiliated Director who serves as the Chair of the Nominating & Governance Committee receives an additional fee of \$5,000 cash per year. Also, any Non-Affiliated Director who serves as the Chair of the Board of Directors receives an additional fee of \$150,000 cash per year.

Meeting Fees. For 2011, Non-Affiliated Directors also received a fee of \$2,250 cash for attending each Board meeting and \$1,500 cash (\$2,000 cash in the case of the Audit Committee) for attending each committee meeting on which such individual serves.

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form DEF 14A

Stock-based Awards. Effective July 1, 2011, the Non-Affiliated Directors receive the stock compensation described below:

Each Non-Affiliated Director receives an annual stock award equal in value to \$200,000, 100% of which is restricted stock units. The number of restricted stock units actually awarded to each director is calculated using the closing price as of the date of the grant. The Compensation Committee annually reviews current market data and, if appropriate, recommends to the Board of Directors any necessary adjustment to the expected value of the annual stock award to directors.

Table of Contents

All restricted stock units vest over one year (100% on the first anniversary of the grant date).

The annual stock award grant date is in early March of each year and the exercise price of the securities granted, if applicable, is the closing price on the date of grant.

On March 12, 2012, Non-Affiliated Directors each received:

5,481 shares of restricted stock valued at \$36.49 per share (the closing price on the day of grant), which vest over one year (100% on March 12, 2013).

Directors Stock Election Plan. Under the Directors Stock Election Plan, non-employee Directors may elect to have some, or all of their quarterly retainer and/or meeting fees delivered in the form of Endo Common Stock. The amount of stock will be determined by dividing the portion of cash fees elected to be received as stock by the closing price of the stock on the last day trading of the calendar quarter, which is the day the payment would have otherwise been paid in cash.

Directors Deferred Compensation Plan. The Endo Directors Deferred Compensation Plan provides an opportunity for non-employee Directors to defer receipt of the annual retainer and/or meeting fees (cash or as elected in the form of Endo stock) and RSUs. At the point of distribution, participants will receive the accumulated compensation in a lump sum payment or annual installment payments.

Additional Arrangements. The Company pays for or provides (or reimburses directors for out-of-pocket costs incurred for) transportation, hotel, food and other incidental expenses related to attending Board and committee meetings or participating in director education programs and other director orientation or educational meetings.

Insurance and Indemnification. The Company has retained directors and officers indemnification insurance coverage. This insurance covers directors and officers individually where exposures exist, other than those for which the Company is able to provide indemnification.

Other Information Regarding the Company

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management. The following table sets forth, as of April 9, 2012, the name, address and holdings of each person, including any group as defined in Section 13(d)(3) of the Exchange Act, known by Endo to be the beneficial owner of more than 5% of common stock. Footnote (a) below provides a brief explanation of what is meant by the term beneficial ownership. The following table also sets forth, as of April 9, 2012, the number of shares of common stock beneficially owned by each of the Company's then current directors and the Chief Executive Officer, the principal financial officer and the other three most highly compensated executive officers of the Company as of April 9, 2012. The following table also sets forth, as of April 9, 2012, the number of shares of common stock beneficially owned by all then current directors and executive officers of the Company as a group.

Table of Contents

Name of Beneficial Owner	Number of Shares of Common Stock Beneficially Owned (a)	Percentage of Class (a)
<i>Directors and Executive Officers:</i>		
Roger H. Kimmel (b)	208,167	*
John J. Delucca (c)	47,020	*
Nancy J. Hutson, Ph.D. (d)(o)	25,619	*
Michael Hyatt (e)	307,770	*
William P. Montague (f)	27,233	*
David B. Nash, M.D., M.B.A. (g)	-	*
Joseph C. Scodari (h)(o)	39,044	*
William F. Spengler (i)	38,670	*
David P. Holveck (j)(o)	639,702	*
Alan G. Levin (k)(o)	92,178	*
Julie McHugh (l)(o)	72,422	*
Ivan P. Gergel, M.D. (m)(o)	69,233	*
Caroline B. Manogue (n)(o)	419,504	*
All current directors and executive officers of Endo Pharmaceuticals Holdings Inc. as a group (13 persons)	1,986,562	1.7%
<i>Other Stockholders:</i>		
Capital Research Global Investors (p)	10,600,758	9.1%
Janus Capital Management (q)	8,585,257	7.3%
BlackRock Institutional Trust Company, N.A. (r)	6,773,380	5.8%
Fidelity Management & Research (s)	6,082,831	5.2%
LSV Asset Management (t)	5,859,873	5.0%

*The percentage of the class to be owned by such security holder represents less than 1%.

- (a) Beneficial ownership is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person's name. The term also includes what is referred to as indirect ownership, meaning ownership of shares as to which a person has or shares investment power. For purposes of this table, a person or group of persons is deemed to have beneficial ownership of any shares as of a given date that such person has the right to acquire within 60 days after such date.
- (b) Mr. Kimmel is the Chairman of the Board of Endo. The business address for Mr. Kimmel is c/o Rothschild, Inc., 1251 Avenue of the Americas, New York, New York 10022. Mr. Kimmel's beneficial ownership represents (i) options to purchase 43,167 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2000, 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 165,000 shares of common stock held in trusts for which Mr. Kimmel serves as trustee and as to which shares Mr. Kimmel holds either the sole or the shared power of disposition and power to vote. His beneficial ownership excludes (i) 2,500 shares of common stock held in trusts for the benefit of one of Mr. Kimmel's adult children, as to which shares Mr. Kimmel has neither the power of disposition nor the power to vote, (ii) options to purchase 6,642 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (iii) 5,481 shares of unvested restricted stock units.
- (c) Mr. Delucca is a director of our company. The business address for Mr. Delucca is 314 Ardmore Road, Ho-Ho-Kus, NJ 07423. Mr. Delucca's beneficial ownership represents (i) options to purchase 33,167 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2000, 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 13,853 directly owned shares of common stock. His beneficial ownership excludes (i) options to purchase 6,642 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested restricted stock units.
- (d) Dr. Hutson is a director of Endo. Dr. Hutson's beneficial ownership represents (i) options to purchase 11,617 shares of our common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 Stock Incentive Plan which will be exercisable within the next 60 days and (ii) 14,002 directly owned shares of common stock. Her beneficial ownership excludes (i) options to purchase 6,568 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested restricted stock units.
- (e) Mr. Hyatt is a director of Endo. The business address for Mr. Hyatt is c/o Irving Place Capital, 227 Park Avenue, New York, New York 10172. Mr. Hyatt's beneficial ownership represents (i) options to purchase 58,167 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2000, 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days, (ii) 228,853 directly owned shares of common stock and (iii) 20,750 shares held in trusts for which Mr. Hyatt serves as trustee and as to which shares Mr. Hyatt holds either

Table of Contents

- the sole or the shared power of disposition or the power to vote. His beneficial ownership excludes (i) options to purchase 6,642 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested restricted stock units.
- (f) Mr. Montague is a director of Endo. The business address for Mr. Montague is 9695 Rocky Point, Clarence, NY 14031. Mr. Montague's beneficial ownership represents (i) options to purchase 11,836 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 15,397 directly owned shares of common stock. His beneficial ownership excludes (i) options to purchase 6,642 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested restricted stock units.
- (g) Dr. Nash is a director of Endo. The business address for Dr. Nash is c/o Jefferson School of Population Health, 1015 Walnut Street, Suite 115, Philadelphia, Pennsylvania 19107. Given his March 2011 appointment to the Company's Board, Dr. Nash has no beneficial ownership in the Company as of April 9, 2012. However, he has been granted 5,481 restricted stock units, none of which has vested as of April 9, 2012.
- (h) Mr. Scodari is a director of Endo. Mr. Scodari's beneficial ownership represents (i) options to purchase 15,715 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 23,329 directly owned shares of common stock. His beneficial ownership excludes (i) options to purchase 7,934 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested restricted stock units.
- (i) Mr. Spengler is a director of Endo. The business address for Mr. Spengler is 616 Orchid Avenue, Corona del Mar, CA 92625. Mr. Spengler's beneficial ownership represents (i) options to purchase 15,715 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 22,955 directly owned shares of common stock. His beneficial ownership excludes (i) options to purchase 7,934 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested restricted stock units.
- (j) Mr. Holveck is a director of Endo and is our President and Chief Executive Officer, effective April 1, 2008 and a Director of the Company effective March 25, 2008. Mr. Holveck's beneficial ownership represents (i) options to purchase 600,605 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 39,097 directly owned shares of common stock. His beneficial ownership excludes (i) options to purchase 475,496 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days, (ii) 200,377 shares of unvested restricted stock units and (iii) 164,184 unvested, unearned performance share units.
- (k) Mr. Levin is our Executive Vice President & Chief Financial Officer. Mr. Levin's beneficial ownership represents (i) options to purchase 76,326 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days, (ii) 4,977 directly owned shares of common stock (iii) and 10,875 RSUs which will be converted to common stock within the next 60 days. His beneficial ownership excludes (i) options to purchase 140,137 shares of common stock granted under his employment agreement and the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days, (ii) 61,177 shares of unvested restricted stock units and (iii) 54,394 unvested, unearned performance share units.
- (l) Ms. McHugh is our Chief Operating Officer. Ms. McHugh's beneficial ownership represents options to purchase 72,422 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 Stock Incentive Plan which will be exercisable within the next 60 days. Her beneficial ownership excludes (i) options to purchase 150,116 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days, (ii) 34,967 shares of unvested restricted stock units and (iii) 31,883 invested, unearned performance share units.
- (m) Dr. Gergel is our Executive Vice President, Research & Development & Chief Scientific Officer. Dr. Gergel's beneficial ownership represents options to purchase 69,233 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days. His beneficial ownership excludes (i) options to purchase 137,498 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days, (ii) 61,333 shares of unvested restricted stock units and (iii) 48,938 unvested, unearned performance share units.
- (n) Ms. Manogue is our Executive Vice President, Chief Legal Officer & Secretary. Ms. Manogue's beneficial ownership represents (i) options to purchase 388,669 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2000, 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 30,835 directly owned shares of common stock. Her beneficial ownership excludes (i) options to purchase 109,632 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days, (ii) 45,574 shares of unvested restricted stock units and (iii) 37,709 unvested, unearned performance share units.

Table of Contents

- (o) The business address for this person is c/o Endo Pharmaceuticals Holdings Inc., 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317.
- (p) The business address for this entity is 333 South Hope Street, Los Angeles, CA 90071. This ownership information is based on a Schedule 13G/A filed with the SEC on February 14, 2012 by Capital Research Global Investors.
- (q) The business address for this entity is 151 Detroit Street, Denver, Colorado 80206. This ownership information is based on a Schedule 13G filed with the SEC on February 14, 2012 by Janus Capital Management.
- (r) The business address for this entity is 40 East 52nd Street, New York, NY 10022. This ownership information is based on a Schedule 13G/A filed with the SEC on February 13, 2012 by BlackRock, Inc.
- (s) The business address for this entity is 82 Devonshire Street, Boston, Massachusetts, 02109. This ownership information is based on a Schedule 13G/A filed with the SEC on February 14, 2012 by FMR LLC.
- (t) The business address for this entity is 155 N. Wacker Drive, Suite 4600, Chicago, IL 60606. This ownership information is based on a Schedule 13G filed with the SEC on February 9, 2011 by LSV Asset Management.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 requires our executive officers, directors and greater-than-ten-percent stockholders (collectively, Reporting Persons) to file an initial report of ownership (Form 3) and reports of changes of ownership (Forms 4 and 5) of Endo securities with the SEC and the NASDAQ. These persons are also required to furnish the Company with copies of all Section 16(a) reports that they file with respect to Endo securities. Based solely upon a review of Section 16(a) reports furnished to the Company for the year ended December 31, 2011 and written representations from certain Reporting Persons that no other reports were required, the Company believes that all the Reporting Persons complied with all applicable filing requirements for the year ended December 31, 2011, except that one transaction by Mr. Scodari was not filed on a timely basis (one day late) due to a Company administrative error. This report was subsequently filed.

No Dissenters' Rights

The corporate action described in this Proxy Statement will not afford stockholders the opportunity to dissent from the actions described herein or to receive an agreed or judicially appraised value for their shares.

Other Matters

As of the date of this Proxy Statement, the Board of Directors of the Company knows of no other matters to be presented for stockholder action at the Annual Meeting. However, other matters may properly come before the Annual Meeting or any adjournment or postponement thereof. If any other matter is properly brought before the Annual Meeting for action by the stockholders, proxies in the enclosed form returned to the Company will be voted in accordance with the recommendation of the Board of Directors.

Annual Report/Form 10-K

The Company's 2011 Annual Report to its stockholders is being mailed to all stockholders concurrently with this Proxy Statement. Copies of the Company's Form 10-K as filed with the SEC and any amendments thereto may be obtained without charge by writing to Endo, 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317, Attention: Secretary.

endo | 100 Endo Boulevard | Chadds Ford, Pennsylvania 19317

46

Table of Contents

Stockholder Proposals for the 2013 Annual Meeting

The Company's by-laws require that, for business to be properly brought before an annual meeting by a stockholder, such stockholder must have given timely notice thereof, along with other specified material, in proper written form to the Secretary of the Company. To be timely, a stockholder's notice to the Secretary must be received at the principal executive offices of the Company not less than 60 days and not more than 90 days prior to the anniversary date of the immediately preceding annual meeting. Accordingly, to make a proposal for consideration at our 2013 annual meeting that is timely within the meaning of the Company's by-laws, a stockholder must make certain notice of such proposal is received by the Secretary of the Company no earlier than February 22, 2013 and no later than March 24, 2013. In the event that the annual meeting is called for a date that is prior to April 23, 2013 or after June 22, 2013, notice by the stockholder must be received at the principal executive offices of the Company not later than the close of business on the 10th day following the day on which the 2013 annual meeting is publicly announced or notice of the 2013 annual meeting was mailed, whichever first occurs. Any stockholder who wishes to make a proposal should obtain a copy of the relevant section of the by-laws from the Secretary of the Company. Any proposal (other than a proposal pursuant to Rule 14a-8) that is received after the times specified above for proposed items of business will be considered untimely under Rule 14a-4(c) under the Exchange Act, and the persons named in the proxy for the meeting may exercise their discretionary voting power with respect to such proposal, including voting against such proposal.

In addition, the Company's by-laws require that any stockholder who wishes to submit a nomination to the Board must deliver written notice of the nomination to the Secretary of the Company within the time period and comply with the information requirements specified in Section 10 of Article II of the by-laws relating to stockholder nominations and the procedures set out in this Proxy Statement under the heading "Committees of the Board of Directors and Related Reports Nominating Committee." To be timely, a stockholder's notice to the Secretary must be received at the principal executive offices of the Company (a) in the case of the annual meeting not less than 60 days nor more than 90 days prior to the anniversary date of the immediately preceding annual meeting; provided that in the event that the annual meeting is called for a date that is prior to April 23, 2013 or after June 22, 2013, notice by the stockholder must be received at the principal executive offices of the Company not later than the close of business on the 10th day following the day on which the 2013 annual meeting is publicly announced or notice of the 2013 annual meeting was mailed, whichever first occurs and (b) in the case of a special meeting of stockholders called for the purpose of electing directors, not later than the close of business on the 10th day following the day on which notice of the date of the special meeting was mailed or publicly announced, whichever first occurs. Accordingly, to submit a nomination to the Board for consideration at our 2013 annual meeting that is timely within the meaning of the Company's by-laws, a stockholder must make certain notice of such nomination is received by the Secretary of the Company no earlier than February 22, 2013 and no later than March 24, 2013. Any notice of nomination that is received after the dates specified above will be considered untimely. If the Company does not receive such notice of nomination between such dates, the notice will be considered untimely. Any stockholder who wishes to make a nomination should obtain a copy of the relevant section of the by-laws from the Secretary of the Company.

Proposals of stockholders intended to be included in the Company's proxy statement pursuant to Rule 14a-8 under the Exchange Act at the 2013 annual meeting must be received by us at our principal executive offices addressed to the Secretary of the Company no later than December 28, 2012.

All proposals should be addressed to the Secretary, Endo, 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317.

Table of Contents

Endo
100 Endo Boulevard
Chadds Ford, PA 19317
610.558.9800
endo.com

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR

THE STOCKHOLDER MEETING TO BE HELD ON MAY 23, 2012

The Proxy Statement, annual report to security holders and related materials are available at www.endo.com/investors/financial-reports

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto authorized.

By order of the Board of Directors,

CAROLINE B. MANOGUE
Executive Vice President, Chief Legal Officer & Secretary

Chadds Ford, Pennsylvania

April 27, 2012

endo | AMS Endo Pharmaceuticals HealthTronics Qualitest

Table of Contents

Table of Contents